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Chapter 1 – Introduction
Endocrine disruptors, xenobiotics, environmental obesogens, persistent organic
pollutants and environmental toxicants are all terms used to describe chemicals in the
environment that affect human and/or animal health.

Some are naturally occurring

substances (e.g. mercury, lead, and radon), but the majority are synthetic compounds
(e.g. Bisphenol A, phthalates, pesticides and dioxins) introduced into the environment
by man, only to later discover their deleterious effects on humans and wildlife.
Many naturally occurring (non-synthetic) environmental toxicants fall under the
classification of heavy metals (e.g. lead, mercury, arsenic and cadmium). They are
considered to be persistent environmental contaminants, found in their most basic
elemental forms and can’t be further broken down or destroyed. Multiple health effects
are associated with heavy metal exposure. Arsenic has been shown to cause weight
loss,

central

nervous

system

deficits,

respiratory

and

reproductive

system

complications, and diabetes and lung cancer [1-4]. Mercury exposure has been shown
to affect renal, respiratory, cardiovascular, gastrointestinal and central nervous systems
[5]. Lead (Pb) exposure has been associated with loss of cognitive function, renal and
central nervous system impairments, hypertension, anemia and thyroid hormone
imbalances [6-16]. Although the sources of some of these heavy metals, such as Pb,
have been eliminated (e.g. from paints and gasoline), other Pb-containing sources like
industrially contaminated soils and turn-of-the-century housing, prevalent in urban areas
like Detroit, remain a significant exposure risk throughout residents’ lifetimes [17-20].
Synthetic, or man-made toxicants, are numerous and pose risks for diseases
associated with exposure [21].

Synthetic toxicants include, but are not limited to,

2
polybrominated diphenylethers (PBDEs), polychlorinated biphenyls (PCBs), phthalates,
organochlorinated pesticides (e.g. DDT), Bisphenol A (BPA), perfluorinated compounds
(PFCs)

and

dioxin

(2,3,7,8-tetrachlorodibenzo-p-dioxin,

TCDD)

or

dioxin-like

compounds. PBDEs are flame retardant chemicals known to impair liver and thyroid
function as well as cause cancer [22-24].

Phthalates increase flexibility in plastics

products, are used to add fragrances to everyday items, and are known to cause
testicular dysgenesis, asthma and have recently been linked to thyroid dysfunction,
obesity and diabetes [25-29]. Dioxins are a by-product of plastics manufacturing, they
are known to affect whole-body energy metabolism and interfere with thyroid function as
well as cause peripheral insulin resistance, cancer and diabetes [30-42].
An important and unresolved question in the environmental health field is
whether exposure to common environmental toxicants, such as dioxin and heavy metal
like Pb, increase the risk of developing diabetes, especially in those populations
subjected to concomitant risk factors such as obesity. Currently, 11.3% of adults in the
US are diabetic and NIH reports indicate steady increases in diabetes diagnoses since
1990 [43]. Obesity, which is found in greater than one third of the US population (72
million people), is strongly associated with diabetes and the metabolic syndrome [44].
High obesity rates may be attributed to the social/behavioral stressors of physical
inactivity and over-nutrition, yet this issue can be viewed from the perspective of
potential pathological interactions between different classes of environmental stressors chemical (exposure to environmental toxicants) and social (lifestyle behaviors leading to
obesity).
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With a vast array of literature describing its deleterious effects, dioxin is one of
the most studied environmental toxicants. Links have been established between dioxin
exposure and peripheral insulin resistance, however, there was no evidence of elevated
blood glucose levels or fasting hyperglycemia [35, 39, 42, 45-47]. The development of
insulin resistance is correlated with an increased risk of developing diabetes and is a
clinical symptom of type 2 diabetes mellitus as are elevated blood glucose levels and
fasting hyperglycemia.

Data suggests that exposure to dioxin may result in the

suppression of hepatic glucose production causing hypoglycemia due to increased
insulin levels and/or transcriptional suppression of phosphoenolpyruvate carboxykinase
(PEPCK) gene expression [30, 34, 38, 39, 47]. While dioxin exposure is not prevalent
in human populations, the mechanism of action is well established having been found to
be primarily mediated by activation of the aryl hydrocarbon receptor (AhR) [48-54].
In contrast to dioxin, the mechanism of action for the physiological effects of Pb
exposure is less well established, however, human exposures are much more
widespread. Pb is of particular interest because there is some evidence that exposure
affects metabolism and data presented herein suggests that chronic Pb exposure
contributes to development of diabetes in obese rats. The Pb-obesity interaction is a
relevant issue in large sections of the US population where environmental stressors of
over-nutrition (taking in more calories than the body needs) and an inactive or sedentary
lifestyle are common and co-exist with exposure to persistent environmental toxicants,
such as Pb. This is certainly the case in the City of Detroit where obesity and diabetes
rates are above the national average, and Pb exposure is relatively common (described
in more detail in the Background).
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The overall goal of our lab is to examine the possibility that exposure to
environmental toxicants increases the susceptibility and/or severity of diabetes in
metabolically and nutritionally stressed populations. The goal of this PhD project is twofold: 1) characterize the effect and determine the molecular mechanism of dioxin
exposure on hepatic gluconeogenic gene expression and 2) characterize the effect of
Pb exposure on diabetes risk in metabolically stressed rodents and identify the
molecular and cellular mechanisms by which it affects metabolic balance. These

are

initial steps in a broader research objective to determine if there is a cooperative
interaction between environmental toxicant exposure and additional stressors from the
physical and social environment that promote metabolic instability and disease.
Results from this work could have a significant impact on how we view the
interaction of environmental toxicants with behavioral and lifestyle stressors in humans,
and may compel others to carry out epidemiologic studies to assess the risks of toxicant
exposure in metabolically and nutritionally stressed populations. The in vivo models
developed here may prove useful in developing therapies to reduce the deleterious
effects of Pb exposure in at-risk humans. Finally, the in vitro systems that I establish will
be of general utility for research on the interaction of other environmental toxicants and
metabolically stressed individuals.
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Chapter 2 – Background
2.1 – Diabetes
Diabetes is a leading cause of death and disability in the United States, affecting
over 10% of the adult population.

More alarming than the diagnosed diabetes

percentage is the estimation that 26% of the adult population has impaired fasting blood
glucose, defined as fasting blood glucose levels between normal and diabetes
(>100mg/dL - <125mg/dL) [55]. These estimations point to greater than one quarter of
the population having, or being likely to develop, diabetes [56].

The incidence of

diabetes has been increasing steadily, with the number of diagnosed cases increasing
approximately 2.5-fold between 1990 and 2005 [56]. Although the causes of the high
incidence and increasing rate of diabetes are not well understood, multiple
environmental factors have been suggested to contribute to disease susceptibility. In
particular, environment/lifestyle factors such as over nutrition (caloric overload) and
physical inactivity (sedentary lifestyle) are believed to increase susceptibility to diabetes.
These factors are hypothesized to contribute to the parallel rise in obesity (estimated to
be 32% in 2007), which contributes to diabetes susceptibility in complex and poorly
understood ways.
Research studies have enhanced the appreciation of the integral involvement of
molecular mechanisms such as oxidative stress and inflammation in the development of
insulin resistance and diabetes [57-59]. One of the earliest detectable precursors of
type 2 diabetes, and a known contributor to the development of hyperglycemia, is
insulin resistance [60]. Hyperglycemia has been linked to the presence of oxidative
stress as well as increased production of reactive oxygen species (ROS), all of which
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can exacerbate insulin resistance [60-62]. Studies have shown that levels of oxidative
stress biomarkers are altered in diabetics and people who are insulin resistant [63-65].
The mechanisms by which hyperglycemia induces oxidative stress are not fully
understood. One possible scenario is that changes in cellular metabolism caused by
hyperglycemia alter mitochondrial function leading to overproduction of superoxide
radicals (O2˙-) by the mitochondrial electron transport chain [58, 59, 62, 66-74].
Likewise, the mechanisms by which elevated ROS increase insulin resistance and other
diabetes-related parameters are poorly understood. Possible links between ROS and
insulin resistance include increased levels of advanced glycation end-products (AGE),
increased polyol and/or hexosamine pathway fluxes, and activation of specific protein
kinase C (PKC) isoforms.

Hyperglycemia has been shown to induce each of the

aforementioned processes; even a postprandial acute rise in glucose levels can induce
these processes [60, 61].
Increased ROS production can also stimulate activation of inflammatory signals
(tumor necrosis factor-α [TNF-α]) and stress-response genes (JNK/SAPK, p38 MAPK,
NF-κB), and inflict oxidative damage that interferes with the insulin signaling pathway
[62, 70, 72, 75-92]. ROS presence is increased in diabetes [57, 60, 93] and obesity [58,
94], where the presence of ROS has been coupled with a chronic low-level
inflammatory condition [62].

It has been demonstrated that diabetics exhibit an

abnormal response to hyperglycemia with reduced antioxidant enzyme expression [95,
96]. The reduction in antioxidant enzyme expression does not allow the cell to detoxify
the ROS adequately, resulting in elevated levels of oxidative stress, cellular damage
and inflammatory mediators, all of which can interfere with insulin signaling.
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There are regional variations in diabetes rates suggesting that exposure to
specific localized environmental conditions may also influence disease susceptibility.
Although there are many reasons for regional variations in disease rates, one possibility
is that specific environmental contaminants present in some areas increase
susceptibility to certain diseases. Environmental toxicants such as dioxin and heavy
metals such as lead (Pb) have been shown to cause oxidative stress both in vivo and in
vitro [32, 97]. Exposure to Pb and dioxin has been shown to influence metabolism and
may, therefore, increase susceptibility to Type 2 diabetes in exposed individuals [39, 57,
98-100]. Given the relationship between oxidative stress and diabetes, exposure to
environmental toxicants capable of causing oxidative stress is likely to increase
diabetes susceptibility.

2.2 – Glucose Production and Utilization
A significant portion of my thesis work is focused on the effects of environmental
toxicants on glucose homeostasis in general and hepatic glucose metabolism in
particular. The following is a brief overview of the relevant physiologies.
The balance between glucose production and utilization is regulated by a
network of hormones, neural pathways, and metabolic signals. Insulin plays a pivotal
role in this process.

In the fasting state, insulin secretion is low, which leads to

increased gluconeogenesis in the liver and kidneys and increased glucose generation
by the breakdown of liver glycogen. In the fed state, insulin released from pancreatic βcells reverses this process by inhibiting glycogenolysis and gluconeogenesis, enhancing
peripheral glucose uptake and utilization, and lipogenesis and protein synthesis. The
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net result is that excess glucose is converted to glycogen, triglycerides (TGs), and
protein. When more glucose is present in liver cells than can be metabolized or stored
as glycogen, insulin causes the excess glucose to be converted into free fatty acids
(FFAs). These FFAs are packaged as TGs in VLDL, transported in the blood in this
form, and deposited as fat in adipose tissue.

2.3 – Gluconeogenesis and Regulation of Gluconeogenic Gene Expression
Phosphoenolpyruvate carboxykinase (PEPCK) is the rate-limiting enzyme in the
gluconeogenesis pathway, its regulation is controlled primarily at the level of gene
transcription and it is central to the management of hepatic glucose production during
fasting [101].

The crucial role of PEPCK in controlling the temporal fluctuations in

hepatic glucose output, and the fact that its regulation occurs mainly at the level of
transcription, has made the PEPCK promoter one of the most highly studied
transcriptional regulatory regions in the eukaryotic genome. The signaling pathways
and many of the transcription factors and cofactors that mediate the hormonal
regulation of PEPCK gene transcription have been identified and a large number of
molecular tools are available for studying the transcriptional regulation of this gene. The
combination of its central role in the regulation of hepatic glucose metabolism, and our
detailed understanding of how its transcriptional activity is regulated, make the PEPCK
gene an ideal candidate for deciphering the molecular effects of environmental toxicants
on the regulation of hepatic glucose production [101]. The regulatory mechanisms that
control the transcriptional activity of the PEPCK gene in response to metabolic signals
are complex and full description is beyond the scope of this background section. Only
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those specific regulatory mechanisms that control PEPCK gene transcription that are
relevant to this project will be discussed.
Between meals and during a fast, the liver contributes to blood glucose level
maintenance by increasing gluconeogenesis and glycogenolysis.

The increase in

gluconeogenesis under these conditions is mediated by glucagon, and to some degree
glucocorticoids. Glucagon stimulates PEPCK gene transcription by activation of the
PKA signaling pathway and the stimulation of the transcription factor CREB (Fig. 1,
Fasted). CREB stimulates PEPCK gene expression via direct action on the PEPCK
promoter as well as by stimulating expression of PPARγ co-activator 1-α (PGC1-α).
PGC1-α is a well-characterized transcriptional co-factor for many metabolic genes [102]
and functions as a transcriptional co-activator for HNF4-α, a key component of the
PEPCK transcriptional complex [102, 103].
After a meal, glucagon levels fall and insulin levels rise, setting off a chain of
events that result in the down-regulation of PEPCK gene expression. Without glucagon
present, PKA is no longer stimulated and CREB activation declines. As CREB activity
falls, its stimulatory effect on both PEPCK and PGC1-α is reduced. The loss of PGC1α also reduces the transcriptional activity of HNF4-α, which together contributes to a
reduction of PEPCK transcription.

Finally, insulin activates Akt, which directly

phosphorylates forkhead box protein O1 (FoxO1), causing its nuclear exclusion (Fig. 1,
Fed). The loss of FoxO1 from the nucleus further contributes to the down-regulation of
PEPCK expression by insulin.

The overall effect of these events on PEPCK gene

transcription leads to a decrease in hepatic glucose production. External signals, such
as exposure to environmental toxicants that alter the activity of any of these signaling
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molecules or transcription factors and co-factors could have a significant effect on
hepatic glucose production and whole body glucose homeostasis.

Fig. 2.1 – Regulation of PEPCK gene transcription.
In the fasted state, PEPCK is stimulated by glucagon (top), and in the
fed state is suppressed by insulin (bottom).

11
2.3 – Toxicants Known to Affect Diabetes Susceptibility
The incidence of diabetes in the US population is at an all-time high and is
continuing to rise each year. Although little progress has been made in slowing the
growth of the disease, great strides have been made in our understanding of the
molecular causes of diabetes and its associated metabolic abnormalities such as insulin
resistance, obesity, hyperlipidemia and hypertension.

One result of this increased

knowledge is an appreciation of the important role that oxidative stress plays in the
development of the disease [57-59]. Many toxicants, and in particular metals, are known
to induce oxidative stress in exposed cells and organisms (reviewed in more detail
below). Given the clear role of oxidative stress in diabetes it seems reasonable to ask if
exposure to environmental toxicants, especially those with pro-oxidant activity, could
increase susceptibility to diabetes and related metabolic disorders.
This is an especially relevant question if one considers the pervasiveness of
environmental toxicants in industrialized countries. Taken together, these issues can be
rephrased into a simple, experimentally approachable question, does exposure to
specific environmental toxicants increase diabetes susceptibility or severity. There is
some evidence that general exposures to environmental toxicants can affect diabetes
susceptibility.

For example, a recent report demonstrated that individuals living in the

vicinity of known toxic waste sites were more likely to be hospitalized for diabetes then
individuals living further from such sites [104]. While a specific toxicant cannot be
implicated in this study, it supports the general idea that toxicant-induced environmental
stress increases the risk of developing diabetes.
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Obviously, all toxicants do not affect physiology by the same molecular
mechanism. Different toxicants affect expression of the distinct sets of genes, and alter
the activities of different enzymes. Even with regard to the effect of metals on diabetes,
there are wide differences in which aspects of diseases are affected by exposure to
different toxicants. Cadmium (Cd) has been shown to increase G6Pase, fructose-1,6bisphosphatase, PEPCK and total hepatic glucose output both in vivo and in vitro [105108]. Arsenic (Ar) has been shown to induce changes in expression of genes related to
Type 2 diabetes and many diabetics have been shown to have high body burdens of Ar
[109-112]. Mercury (Hg), Pb, Cd and Ar have all been shown to induce oxidative stress
and the formation of ROS [106, 113-124], which have been associated with increased
insulin resistance [60-62].
Persistent organic pollutants (POPs) and organochlorinated pesticides like PCBs
and DDT exposure were found to be significantly associated with diabetes diagnoses
when NHANES data were evaluated by Everett et.al. [125]. A 2009 study of Great
Lakes sport fishermen found that, of those subjects that were diabetic, they also
possessed much higher body burdens of both PCBs and p,p’-diphenyldichloroethene
(DDE, a congener of DDT) [126]. Finally, Vasiliu et.al. found a statistically significant
relation between female diabetics and blood levels of PCBs, but not with male diabetics
[127].
More recently, studies have found an association between increased waist
circumference, insulin resistance and blood levels of phthalates, indicating a link not
only between phthalate exposure and diabetes, but also between phthalates and
obesity [29, 128, 129]. Bisphenol A (BPA) exposure has been linked to an increased
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risk of obesity [130] as well as adiponectin inhibition (leading to a loss of insulin
sensitivity), hyperinsulinemia, insulin resistance and glucose intolerance in rodents
[131-133]
Because many of the known environmental toxicants are bioaccumulative, and
exposure can occur repeatedly throughout life, the effects of exposure may not be fully
evident until later in life. While it is known that toxicants are capable of causing effects
alone, scientists are just beginning to explore multiple toxicant exposures, and evidence
thus far demonstrates greater detrimental effects in co-exposure scenarios.

Overall, it

is clear from the findings presented above (which are representative of a larger body of
data), that in general exposure of the population of environmental toxicants is likely to
have a significant impact on metabolic disease susceptibility.

2.4 – Dioxin
My initial foray into exploring mechanisms by which environmental toxicants
affect metabolic regulation examined the effects of dioxin on hepatic gluconeogenesis
(described in Chapter 4, below).

The following is a brief summary of background

information on dioxin designed to provide the necessary information for this part of the
study.
Dioxins are a group of widely disseminated, persistent environmental
contaminants that can have effects on whole-body energy metabolism [30-34]. In both
in vitro and in vivo models, dioxin exposure has been shown to increase superoxide
dismutase (SOD) activity and oxidative stress enzymes, and to cause peripheral insulin
resistance [32, 35, 36, 134].

Peripheral insulin resistance is correlated with an
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increased risk of developing diabetes and is a clinical symptom of type 2 diabetes
mellitus [135-137].

2.4.1 – Dioxin and Diabetes
There is clear evidence that dioxin exposure increases the risk of developing
insulin resistance, a condition that often precedes and always accompanies Type 2
diabetes. In in vivo models subjected to a high fat sucrose diet, obesity and insulin
resistance were observed although the animals did not develop full-scale diabetes [36].
Similar findings have been reported in human subjects. A recent analysis of diabetes
parameters in human epidemiological studies conducted on Vietnam veterans from
Operation Ranch Hand, as well as persons subjected to accident or work-related dioxin
exposures, patients showed a strong positive correlation between dioxin exposure,
hyperinsulinemia and insulin resistance [31, 33, 35-37, 138, 139]. Interestingly, these
same subjects did not demonstrate abnormal fasting blood glucose levels, fasting
hyperglycemia and were not diabetic [31, 33, 35, 37, 138], suggesting that one of the
effects of dioxin exposure may be to suppress hepatic glucose output.
This would be consistent with observations from dioxin treated rats where
hypoglycemia was observed that was caused, at least in part, by reduced hepatic
glucose production [30, 47, 140]. Together, these findings suggest that dioxin inhibits
hepatic glucose production by suppressing expression of gluconeogenic genes. Such
results have indeed been reported for the hepatic gluconeogenic genes PEPCK and
glucose-6-phosphatase (G6Pase) [30, 34, 38, 39, 47, 140], although not all studies
were in agreement with these observations [99].

Although its effects on metabolism
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are obviously not well understood, dioxin is a clear example of an environmental toxin
that modulates metabolism in a way that could interact negatively with other deleterious
environmental conditions (e.g. over-nutrition and inactivity) to alter susceptibility to
diabetes.

2.4.2 – Aryl hydrocarbon Receptor Primarily Mediates Dioxin Effects
The effects of dioxins are primarily mediated by activation of the aryl hydrocarbon
receptor, AhR [48-54]. However, my data (described in this thesis) and a previously
published study have suggested an alternative mechanism whereby dioxin may be
suppressing PEPCK and G6Pase gene expression, via activation of AMPK [34]. AMPK
is a cellular energy-sensing protein that is activated when AMP levels within the cell
become high [141]. The ability of AMPK to suppress the key gluconeogenic genes
PEPCK and G6Pase demonstrates its importance as a regulator of hepatic glucose
production and as a potential target of dioxin. While the effects of dioxin on AMPK and
energy metabolism are not clearly understood, AMPK regulates a variety of metabolic
pathways and its activation by an environmental toxicant would constitute a mechanistic
link between toxicant exposure and the regulation of metabolism.

2.4.3 – Hypotheses and Aims of Dioxin Project
It is clear that dioxins are a persistent environmental contaminant with the ability
to influence glucose metabolism and possibly lead to alterations in diabetes
susceptibility.
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Because of this possibility, the following hypotheses were formed: (1) Exposure
to dioxin alters hepatic gluconeogenic gene expression. (2) Dioxin-mediated AMPK
activation contributes to the suppression of hepatic glucose production. These
hypotheses were tested by two specific aims: (1) Characterization of the effect of dioxin
on hepatic gluconeogenic gene expression. (2) Determination of the molecular
mechanism(s) by which dioxins alter PEPCK gene expression.

2.5 – Lead (Pb)
The majority of this thesis is focused on the effects of Pb exposure on diabetes
susceptibility in obese rodents (described in Chapters 5 and 6, below). The following is
a brief summary of background information on Pb designed to provide the necessary
information for this part of the study.
Pb is a persistent environmental contaminant that is found in high levels in many
urban and industrial areas.

Although it has been studied extensively in relation to

cognitive and behavioral effects, little attention has been given to its potential
involvement in metabolic diseases such as diabetes. The Pb-obesity interaction is a
relevant topic in large sections of the US population where environmental stressors of
over-nutrition (taking in more calories than the body needs) and an inactive or sedentary
lifestyle, are common and co-exist with exposure to persistent environmental toxicants,
such as Pb. This is the case in the city of Detroit where obesity and diabetes rates are
above the national average, and Pb exposure is relatively common (as described
below).
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In spite of the fact that there are no epidemiological studies directly addressing
the possibility that Pb exposure enhances diabetes severity, there are several lines of
evidence, in addition to my findings in obese rats, suggesting that Pb exposure
promotes metabolic instability and diabetes.

2.5.1 – Pb Exposure in the Human Population
Although Pb exposure and blood lead levels have generally declined over the
past decade, Pb body burdens continue to rank as major health concerns, particularly in
urban areas and especially in young children and adolescents [142]. Sources of Pb
exposure include pre-1950s housing (e.g. over 38,000,000 homes), lead based paint
available until the 1970s, and contaminated soil in areas surrounding existing superfund
hazardous waste sites, neighborhood industrial activities, and pre-existing conditions,
such as the former presence of Pb smelters in urban neighborhoods.

The highly

industrialized areas with existing Pb contamination largely contain urban underprivileged/under-served populations. In the city of Detroit for example, 6.4% of children
under the age of 6 were classified as having elevated blood lead levels (> 10 μg/dL) by
the Michigan Department of Human Health in 2003 [143].
Pb is a ubiquitous contaminant with long half-life in vivo (10 to 38 months
depending on exposure, blood and bone levels), which could increase the long-term
effects of a limited exposure to Pb. It is found in nature as a divalent cation [144], and
has no known biological function in humans. Pb has been shown to interfere with Fe,
Zn2+, Ca2+ & Ca2+ -regulated events [145, 146], and to bind phospholipids thereby
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altering membrane permeability [147]. Any of these actions could have multiple and
widespread secondary effects on many aspects of cellular and organismal physiology.

2.5.2 – Pb Causes Oxidative Stress, a Risk Factor for Diabetes
Like many toxicants, Pb induces oxidative stress in vitro and in vivo, a known risk
factor for the development of insulin resistance and diabetes [57, 93]. The ability of Pb
to catalyze oxidative reactions and generate reactive oxygen species (ROS) has been
demonstrated in numerous studies [97]. Although the mechanism by which Pb acts as
a pro-oxidant is not fully understood, it is due, at least in part, to direct inhibition of the
heme biosynthetic pathway enzyme δ-aminolevulinic acid dehydratase (δ-ALAD).
Inhibition of δ-ALAD leads to elevated levels of the enzyme’s substrate, δ-aminolevulinic
acid (δ-ALA), a known pro-oxidant that stimulates ROS production, lipid peroxidation,
oxidative stress and is present in the blood and urine of Pb-exposed individuals [148].
Pb also directly inhibits glutathione reductase, and binds protein sulfhydryls, thereby
contributing further to oxidative stress in cells and tissues. Markers of oxidative stress
can be detected in blood, RBCs, serum, and urine of Pb exposed individuals [97].
Recent studies revealed a strong association of blood Pb with markers of oxidative
stress in the general population, and suggested that oxidative stress should be
considered in the development of Pb-mediated diseases, even among people with
relatively low environmental exposure to Pb (i.e. <10 μg/dL) [142].
Pb-induced oxidative stress is relevant to my hypothesis that Pb exposure
promotes the formation of diabetes. Oxidative stress is thought to promote the diabetic
state by direct effects on cellular signaling pathways that influence insulin signaling.
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Subjects exposed to Pb have increased ROS production, oxidative stress induction and
elevated concentrations of δ-ALA in their blood and urine [120, 149-151].

One

proposed mechanism is that ROS activate intracellular signaling through JNK/SAPK,
p38 MAPK and NF-κB. JNK activation results in serine phosphorylation and inhibition of
IRS (Insulin Receptor Substrate) 1 and 2. IRS1 and IRS2 are required for downstream
signaling through additional serine/threonine kinases and their phosphorylation by JNK
results in decreased insulin signaling and insulin resistance (for a review see [57]).

2.5.3 – Previous Studies on the Effect of Pb on Metabolic Parameters in Rodents
Although there is little recent work that addresses the effect of Pb on metabolism
in animal models, three papers published in the 1970s and 80s suggested that Pb
exposure could induce hepatic insulin resistance in rats. Singhal et al. [152] reported
that male rats treated with Pb acetate for 45 days (IP injection), showed a dosedependent increase in amounts of the gluconeogenic enzymes PEPCK and G6Pase in
the liver.

Consistent with these Pb-induced increases in gluconeogenic gene

expression, this study also reported a significant, dose-responsive increase in fasting
blood glucose. A similar finding was reported by Stevenson et al. in young female rats
exposed to 20, 40 or 80 ppm Pb for 56 days in drinking water [153]. These animals also
showed a Pb dose-responsive increase in PEPCK and G6Pase enzyme levels in the
liver and significantly elevated fasting blood glucose.

Finally, Whittle et al.

demonstrated that even small increases in blood lead levels from a control level of
7.9±1.4 µg/dL to 13.8±1.3 μg/dL, for 42 days caused a significant increase in expression
of hepatic gluconeogenic enzymes in rats [154].
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When taken together, these data suggest an interesting possibility that Pb
exposure induces hepatic gluconeogenic gene expression, which would contribute to
elevated blood glucose levels. However, these studies are somewhat dated and limited
in scope - they did not include direct measurements of gene expression, and examined
only minimal physiological parameters related to diabetes. Updated techniques may
also allow for the investigation of the molecular mechanism behind the deleterious
effects of Pb.

2.5.4 – The Potential Link Between Pb and Rev-erb-α
Emerging evidence indicates that components of the circadian clock machinery
can regulate expression of metabolic genes, including PEPCK, G6Pase and PGC1-α
[155]. This evidence was further support by data gathered from mice with mutated
Clock genes showing abnormal gluconeogenic gene expression [156-158]. However,
the mechanism that links metabolic gene expression to circadian clock rhythms remains
poorly understood.
Recently, studies have shown that heme functions as an endogenous ligand for
the orphan nuclear receptor Rev-erb-α (NR1D1), a known component of the circadian
clock machinery [159]. Rev-erb-α is highly expressed in multiple tissues including liver,
and functions as a heme-dependent transcriptional repressor [160-163]. Heme binding
to Rev-erb-α suppresses the transcription of Rev-erb-α target genes including PEPCK,
G6Pase and PGC1-α [155, 157, 158, 161, 162]. Thus, in the absence of heme, the
gluconeogenic program is elevated [132].

The well described effect of Pb in the

inhibition of heme biosynthetic enzymes [164-167] (described above) raises the

21
possibility that Pb exposure will contribute to elevated gluconeogenesis by reducing the
suppressive effect of Rev-erb-α on gluconeogenic gene expression.

2.5.5 – Hypotheses and Aims of Pb Project
The overall goal of the Pb portion of my PhD project is to fully characterize the
effect of Pb exposure on diabetes risk in metabolically stressed (obese) rodents, and to
identify the molecular and cellular mechanisms by which it affects metabolic balance.
The specific goals were to establish in vivo and in vitro models to study the
physiological and molecular mechanisms by which Pb affects insulin sensitivity and
glucose homeostasis.

This was an initial step in a broader research objective to

determine if there is a cooperative interaction between environmental toxicant exposure
and additional stressors from the physical and social environment that promote
metabolic instability and disease.
Together, these ideas formed the underlying hypothesis of my project, that in
combination with metabolic stresses like obesity, Pb exposure increases diabetes
susceptibility and severity.

The work was divided into two specific aims: (1)

Characterize the extent to which Pb exposure promotes diabetes in two well-established
rodent models of metabolic disease (Zucker Diabetic Fatty [ZDF] rats and human Islet
Amyloid Polypeptide [hIAPP] transgenic mice) and determine the dependence of Pbinduced diabetes on obesity and diet composition, (2) Characterize the mechanism by
which Pb alters hepatic insulin sensitivity and gluconeogenesis.
Data generated from this work could have a significant impact on how we view
the interaction of environmental toxicants with other behavioral and lifestyle stressors in
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humans, and may provide the impetus to carry out epidemiologic studies to assess the
risks of toxicant exposure in metabolically & nutritionally stressed populations. If such a
link was observed in the human population, the animal models developed here may
prove useful in developing therapies to reduce the deleterious effects of Pb exposure.
Finally, the model systems established in this study will be of general utility for research
on the interaction of other environmental toxicants and metabolically stressed
individuals.
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Chapter 3 – Materials and Methods
3.1 – Zucker Diabetic Fatty Rats
Female Zucker Diabetic Fatty rats (ZDF-Leprfa/Crl; stock 370 (OBESE)) 6 weeks
of age, were purchased from Charles River Laboratories, Portage, Michigan. Animal
protocol (#A 07-16-08) for ZDF rats was approved by the Institutional Animal Care and
Use Committee at Wayne State University.
Two groups (n=4) of female ZDF fa/fa rats were treated with 0.05% w/v Pb
acetate (PbAc) in the drinking water, which has been previously determined to generate
a blood lead level of approximately 40-50 g/dL in rats [154]. Control animals received
equimolar acetate in drinking water in the form of Na acetate (NaAc).
Animals were housed on paper bedding for the duration of the study because
animals can ingest corncob bedding during a fast, which can alter fasting blood glucose
measures. All animals were fed a standard chow diet (Purina 5008) from weeks 0 – 20,
then switched to a high fat diet (RD 13004, 45% calories from fat diet, Research Diets,
Inc.) from week 20 through termination (week 25). Food and water were offered ad lib.
Body weights and food consumption were measured weekly. Food consumption was
assessed by weighing the amount of food provided at the beginning of each week and
subtracting the amount remaining at the end of the week. While this method is not as
accurate a measure of food consumption as would be obtained in a metabolic cage, it
can reveal gross differences in nutritional intake.
Fasting blood glucose (FBG) measures were obtained from whole blood using a
Hemocue glucometer at weekly intervals (from the saphenous vein) after a 6 hour fast
beginning at 4:00 am, until week 20 (start of high fat diet) when they were taken bi-
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weekly. After the fasting blood glucose measurement was completed, a total of 400µL
of blood was collected and mixed with 3.73µL of 0.5M EDTA, to attain a final
concentration of 4.67mM EDTA per sample, placed on ice immediately and spun in 4°C
centrifuge at 8,500g for 20 minutes. Plasma was removed from packed RBCs and
placed into new 0.5mL centrifuge tube in 25µL aliquots. Both plasma and packed RBCs
were place into storage at -80°C to be utilized for further metabolic measures (See
Table 2.1 for a list of metabolic measures).
Oral glucose tolerance tests (OGTTs) were conducted on each animal once
every four weeks after a 6 hour fast beginning at 4:00 am. Animals were given a bolus
of 50% glucose equivalent to 2mg/g body weight, by oral gavage and blood glucose
was measured using a Hemocue glucometer from 5μL of blood removed from the
saphenous vein. Time points were at 0 (prior to glucose bolus), 15, 30, 60 and 120
minutes.
Blood Pb levels in these samples were determined using standard assay
protocols for measuring patient blood Pb levels at Detroit Medical Center University
Laboratories by atomic absorption spectrometry. Packed red blood cells were
resuspended to a final volume of 2mL in 0.9% physiological saline and measured on a
Hitachi Z-2000 with Zeeman background correction.
Animals were sacrifice at 25 weeks following a 6 hour fast/ 2 hour re-feeding
protocol by CO2 asphyxiation and exsanguination by cardiac puncture.

Relevant

tissues were removed, subdivided and placed in 4% buffered formalin at 4ºC, flashfrozen or frozen in OTC (See Table 2.1 for a list of tissues).

25
3.2 – hIAPP Transgenic Mice
Dr. Steven E. Kahn (Dept. of Veterans Affairs, Puget Sound Health Care System,
Seattle, WA) generously supplied hIAPP transgenic male C57 Black 6 (C57Bl6) mice
[168]. Females, 5-6 weeks old C57Bl/6J mice (stock no. 000664) and males, 6 weeks
old DBA/2J (stock no. 000671) were purchased from Jackson Laboratories (Bar Harbor,
ME). Animal protocol (#A 08-15-10) for hIAPP mice was approved by the Institutional
Animal Care and Use Committee at Wayne State University.
Four hIAPP transgenic male C57Bl6 mice were bred with four female C57Bl/6J
mice. Female progeny were weaned at 3 weeks of age, tail-clipped for genotyping and
ear notched for identification. Female progeny found to be transgene positive were then
bred to male DBA/2J mice. DBA/2J background was utilized to provide a mouse model
with increased insulin secretion, as insulin and islet amyloid polypeptide (IAPP) are cosecreted this model was expected to experience increased amyloid plaque formation
(discussed further in Chapter 6). Male progeny were weaned at 3 weeks of age, tailclipped for genotyping and ear notched for identification. Transgenic male progeny
were separated and utilized for this study as previous studies observed a negative
influence of estrogen on expression of the hIAPP transgene [169, 170] . Breeding and
genotyping were conducted in the laboratory of Dr. Paul Stemmer.
Four groups of male hIAPP mice were established. Two groups (n=16) were
treated with 0.02% w/v PbAc (“high treated”) or equimolar NaAc (“high control”) in the
drinking water. The other two groups (n=12) were treated with 0.005% w/v PbAc (“low
treated”) or equimolar NaAc (“low control”) in the drinking water. Animals began PbAc
or NaAc treatment at 10 weeks of age.
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Animals were housed on paper bedding for the duration of the study because
animals can ingest corncob bedding during a fast, which can alter fasting blood glucose
measures. All animals were fed a standard chow diet (Purina 5009) until weaned, then
placed on a high fat chow diet (Autoclavable Mouse Breeder Diet 5021, Purina)
containing 9% fat w/w (45% calories from fat) through termination (week 45). Food and
water were offered ad lib. Body weights and food consumption were measured weekly.
Food consumption was assessed by weighing the amount of food provided at the
beginning of each week and subtracting the amount remaining at the end of the week.
While this method is not as accurate a measure of food consumption as would be
obtained in a metabolic cage, it can reveal gross differences in nutritional intake.
Fasting blood glucose (FBG) levels were measured with a Hemocue glucometer
from whole blood obtained at bi-weekly intervals (from the saphenous vein) after an 8
hour fast beginning at 8:00 pm. A total of 200µL of blood was collected and mixed with
18.6µL of 0.05M EDTA to attain a final concentration of 4.67mM EDTA per sample and
placed on ice immediately. A 20µL aliquot of whole blood was separated for blood Pb
level measurements and the remaining sample was spun in 4°C centrifuge at 2,500g for
20 minutes as soon as possible. Plasma was removed from packed RBCs and placed
into new 0.5mL centrifuge tubes in 25µL aliquots. Both plasma and packed RBCs were
place into storage at -80°C to be utilized for further metabolic measures (See Table
2.1).
Oral glucose tolerance tests (OGTTs) were conducted on each animal, to
establish baseline (time 0) glucose tolerance and at 6 months and 9 months of
treatment after an 8 hour fast begun at 8:00 pm. Animals were given a solution of 30%
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glucose equivalent to 1.5mg/g body weight, administered as a bolus via balled gavage
needle. Blood glucose was measured using a Hemocue glucometer from 5μL of whole
blood removed from the saphenous vein. Time points were 0 (prior to glucose bolus),
15, 30, 60 and 120 minutes.
Blood Pb levels were assessed by Dr. Paul Stemmer and Steven Jones using
the ICP-MS facilities in the Biochemistry Department at Wayne State University School
of Medicine. See section 3.5 below for specific protocol.
Sacrifice at 45 weeks was by CO2 asphyxiation followed by cervical dislocation
and exsanguination by cardiac puncture. Relevant tissues were removed by sterile
technique, washed with a solution of ice cold PBS (1x) plus 0.01M EDTA, subdivided,
then either placed in 4% buffered formalin at 4°C, freeze-clamped or flash-frozen in
OTC (See Table 2.1 for a list of tissues).

Table 2.1 – Post-Termination Testing and Tissue Protocols
Blood parameters
Blood Pb levels
Fasting blood glucose
Insulin
Glucose tolerance (OGTT)

Liver Tissue Parameters

Termination (rats)
DMC-UHL (packed RBCs)
Biweekly (20µl, mice) ICP-MS facility at WSU SOM (whole blood)
Weekly (4 µl)
Glucometer (Hemocue) from whole blood
Weekly (20 µl)
Elisa (Millipore)
Every 4 weeks (rats)
Glucometer (Hemocue) from whole blood
0, 6 mo, 9 mo (mice)

Liver histology

At termination

Pancreatic histology

At termination

Triglyceride content

At termination

H & E, Masson’s Trichrome, Periodic Acid
Schiff (fixed sections)
H & E, Masson’s Trichrome, Aldehyde
Fuchsin, Congo Red (mice only)
(fixed
sections)
TG assay (kit from Cayman Chemicals)

PEPCK, G6Pase, PGC1-

At termination

qRT-PCR and western blots; from frozen liver

At termination
At termination
At termination
At termination

From frozen liver tissue
Frozen in OTC for histology
Flash- frozen for RNA and protein analysis
Flash-frozen

Additional tissue samples for future analysis
Liver samples for RNA profiling
Pancreas
Skeletal Muscle (gastroc. & soleus)
Adipose: subQ (inguinal), abdominal (retroperitoneal)
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3.3 – Genotyping
Genotyping of hIAPP mice was done using DNA extracted from tail clip, using a
protocol provided by Dr. Rebecca L. Hull’s laboratory (see reference [168]) and the
previously published protocol by Laird et.al. [171]. Briefly, 0.5 cm of clipped mouse tail
was digested with protease overnight, and DNA was ethanol precipitated from the clear
supernatant after centrifugation. Genotyping was carried out by Ms. NamHee Shin in
Dr. Paul Stemmer’s lab.

3.4 – Tissue Processing and Histological Staining
Tissues were fixed with 4% buffered formalin at 4°C; paraffin embedded, sliced in
5μm sections, affixed to glass slides and allowed to dry. Slides were then stained with
Hematoxylin and Eosin, Aldehyde Fuchsin, Periodic Acid-Schiff, Congo Red or
Masson’s Trichrome, all histological supplies were purchased from American
MasterTech Supplies.

3.4.1 – Deparaffinization and Dehydration
To remove paraffin prior to staining, slides were put through 2 changes of 100%
Xylene for 3 minutes each, followed by 2 changes of 100% EtOH for 3 minutes each, 2
changes of 95% EtOH for 3 minutes each, one change of 75% EtOH for 3 minutes, one
change of 50% EtOH for 3 minutes and running tap water for 1 minute. Slides were
then treated with the staining protocol of choice followed by dehydration and mounting.
To dehydrate after conclusion of staining, slides were dipped into 95% EtOH,
followed by 3 changes of 100% EtOH, once into 1:1 100% EtOH:100% Xylene and 2
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changes of 100% Xylene.

Coverslips were mounted with ClearMount (American

MasterTech) and allowed to dry for 72 hours undisturbed.

3.4.2 – Hematoxylin and Eosin Staining
After deparaffinization, the American MasterTech protocol for Harris’ Hematoxylin
and Eosin (Item# KTHNEPT) procedure was followed. Both pancreas and liver slides
were placed in Harris’ Hematoxylin for 5 minutes followed by running water rinse for 1
minute.

Slides were then dipped into Differentiating Solution 3 times, followed by

running water rinse for 1 minute. Slides were placed in Bluing Solution for 35 seconds,
rinsed in running water for 3 minutes then moved to 70% EtOH for 1 minute. After 60
seconds in Eosin Y Stain, slides were dehydrated, coverslips mounted and dried.

3.4.3 – Aldehyde Fuchsin Staining
After deparaffinization, the American MasterTech protocol for Aldehyde Fuchsin
(Item# STAFU) procedure was followed. Pancreas sections were placed in Aldehyde
Fuchsin Stain for 2 hours, rinsed with 70% EtOH, placed in Light Green Counterstain for
3 minutes then dehydrated, coverslips mounted and dried.

3.4.4 – Periodic Acid-Schiff Staining
After deparaffinization, the American MasterTech protocol for Periodic Acid-Schiff
(Item# KTPAS) procedure was followed. Liver sections were placed in 0.5% Periodic
Acid for 7 minutes, rinsed quickly in distilled water then placed in Schiff’s Solution for 15
minutes. Slides were removed from Schiff’s Solution, rinsed in running water for 5
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minutes, placed in Modified Mayer’s Hematoxylin for 2 minutes then rinsed in running
water for 3 minutes. Slides were then placed in to Light Green Counterstain for 10
minutes, rinsed with 70% EtOH, dehydrated, coverslips mounted and dried.

3.4.5 – Congo Red Staining
After deparaffinization, the American MasterTech protocol for Congo Red (Item#
KTCRE) procedure was followed. Pancreas sections from hIAPP mice were placed in
Congo Red Amyloid Stain for 2 hours, differentiated in 1% Sodium Hydroxide for 30
seconds then rinsed in running water for 5 minutes. Slides were then placed in to
Modified Mayer’s Hematoxylin for 3 minutes, rinsed in running water for 1 minute,
dehydrated, coverslips mounted and dried.

3.4.6 – Masson’s Trichrome Staining
After deparaffinization, the American MasterTech protocol for Masson’s
Trichrome (Item# KTMTR) procedure was followed. Pancreas and liver sections were
placed in to Bouin’s Fluid and left overnight at room temperature. The following day,
they were left in running tap water until the tissue was colorless. The slides were then
placed into Weigert’s Hematoxylin for 5 minutes, rinsed in running water, placed in
Biebrich Scarlet-Acid Fuchsin for 15 minutes and rinsed in distilled water. They were
placed into Phosphomolybdic/Phosphotungstic Acid for 15 minutes, then moved directly
to Aniline Blue Stain for 10 minutes, rinsed in distilled water, placed in 1% Acetic Acid
for 5 minutes, dehydrated, coverslips mounted and dried.
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3.5 – Blood Pb Analyses
The protocol for blood Pb analyses was designed and carried out by Steven
Jones, under the supervision of Dr. Paul Stemmer using the ICP-MS facilities in the
Biochemistry Department at Wayne State University School of Medicine.
Whole blood was collected from the saphenous vein and 20µL transferred to
Eppendorf tubes and stored at -80C. Samples were diluted with two volumes of 0.1%
TritonX-100 added to the storage tube to ensure the protein was dissolved. The clear
samples then were further diluted with 17 volumes of 2% nitric acid spiked with 1 ppb
rhenium (Re) for a final dilution of 20 fold. Solutions were clear of obvious precipitates
prior to addition of the nitric acid and proteins that were soluble in the triton solution
precipitated upon the addition of the nitric acid. The precipitated protein samples were
incubated with the nitric acid for 24 hours then diluted for analysis.
Precipitates were pelleted by centrifugation and supernatants removed to a fresh
tube. Samples from animals that had not received Pb were diluted 3 fold while samples
from Pb-treated animals were diluted 20 fold for a final dilution of 60 or 400 fold
respectively. Standards containing 0, 0.1, 0.3, 0.5, 0.8 and 1.0 ppb Pb in 2% nitric acid
with 1 ppb rhenium were run before and after analysis of the samples. The analysis
was carried out using a PerkinElmer SCI EX ICP-MS (ELAN 9000). The Pb and Re
standards were purchased from Acros Organics. The Pb was 2% in HNO3 and the Re
was 1 mg/ml in water.

32
3.6 – Microscopy
Histological imaging was completed utilizing a Leica D4000b Bright-field
Microscope (Fisher Scientific) with Leica Digital Imaging Software (Fisher Scientific)
housed at the Wayne State University Department of Anatomy and Cell Biology Imaging
and Histopathology Core.

3.6 – Triglyceride Assay
Triglyceride Colorimetric Assay Kit (Item# 10010303, Cayman Chemicals) was
used according to manufacturer’s instructions to assess tissue triglyceride levels.
Briefly, 350mg of liver tissue from both ZDF rats and hIAPP mice was homogenized in
1x Standard Diluent Assay Reagent, centrifuged at 10,000g and 4ºC, supernatant
transferred to new tubes and stored on ice. Samples were diluted 1:9 in Standard
Diluent Assay Reagent (per protocol recommendations for tissue samples). 10µL per
sample were loaded in duplicate and read at 540nm absorbance on VersaMax plate
reader with SoftMax Pro 3.0 software (Molecular Devices). Regression analysis of data
was completed with GraphPad Prism 5.

3.7 – Insulin ELISA
Rat/Mouse Insulin ELISA Kit (Catalog# EZRMI-13K, EMD Millipore) was used
according to manufacturer’s instructions to assess plasma insulin levels in both ZDF
rats and hIAPP mice. Briefly, frozen plasma samples from both ZDF rats and hIAPP
mice were thawed, centrifuged at 2,500g at 4ºC, and the supernatants transferred to
new tubes and stored on ice. Duplicate 20µL samples were loaded into the prepared
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96-well plate and combined with 80μL of Detection Antibody and allowed to incubate for
2 hours. After the incubation, the plate was washed, 100μL of Enzyme Solution added
and incubated for 30 minutes. After a series of 6 final washes, 100μL of Substrate
Solution was added, followed by 100μl of Stop Solution. The samples were then read at
both 450nm and 590nm absorbance on VersaMax plate reader with SoftMax Pro 3.0
software (Molecular Devices).

Regression analysis of data was completed with

GraphPad Prism 5.

3.8 – Cell Culture
Primary rat hepatocytes (PRH) were obtained from Wayne State University’s
Institute for Environmental Health Sciences Cell Culture Core. PRH cells were plated at
a density of 9 x 105 cells per well on collagen-coated (Rat tail collagenase, Invitrogen)
6-well plates (Denville), in 10nM insulin-containing serum-free DMEM (HyClone) and
allowed to recover overnight. PRH cells were changed to insulin-free DMEM 2 hours
prior to initiation of treatment protocols.
Human hepatoma (HepG2) cells were cultured in 100mm dishes with high
glucose

DMEM

(HyClone),

supplemented

with

10%

FBS

and

1%

(v/v)

penicillin/streptomycin. HepG2 cells were plated at a density of 1 x 10 5 cell per well in
6-well plates for gene expression experiments.
FAO rat hepatoma cells, cultured in RPMI 1640 (Invitrogen) supplemented with
10% FBS and 1% (v/v) penicillin/streptomycin. FAO cells were plated at a density of 4.5
x 105 cell per well in 6-well plates for gene expression experiments and 7.75 x 105 in
60mm dishes for western blot experiments.
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H4IIe rat hepatoma cells, cultured in high glucose DMEM (HyClone)
supplemented with 5% FBS, 5% BCS and 1% (v/v) penicillin/streptomycin. H4IIe cells
were plated at a density of 6 x 104 cell per well in 6-well plates for gene expression
experiments. All cell cultures were maintained at 37ºC with a 5% CO2 atmosphere.

3.9 – Western Blotting
Cells were harvested with RIPA buffer, sonicated and cleared (centrifuged for 30
minutes at 13,000g and 4°C). SDS-PAGE gels (pre-cast, Pierce) were loaded with 50µg
protein per lane, one lane with 5uL Easy-Run REC-pre-stained marker (Fisher
Scientific) and run for 1 hour at 40mA. Transfer to nitrocellulose membrane was carried
out overnight at 4ºC and 40mA in a Bio-Rad Mini Protean 3 transfer device.
Nitrocellulose membranes were removed from transfer apparatus, Ponceau stained to
confirm transfer of proteins, washed with TBS-T, blocked with 5% milk in TBS-T for 2
hours followed by overnight incubation with phospho-AMPKSer79, phospho-ACCThr172
(1:1000 in 5% BSA in TBS), total-AMPK or total-ACC (1:1000 in 5% BSA in TBS-T)
antibodies (Cell Signaling Technologies).

After 3 washes in 1x TBS-T buffer,

membranes were incubated with goat-anti-rabbit secondary antibody (1:1000 in 5% milk
in TBS-T, Cell Signaling Technologies) at room temperature for 1 hour. TBS-T was
utilized for washes and ECL (Pierce) was utilized for chemiluminescence. Membranes
were stripped, re-blocked and incubated for loading control with GAPDH.
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3.10 – Gene Expression Analyses
3.10.1 – In Vivo Gene Expression
Total RNA was extracted a small piece of flash-frozen liver tissue using
SpinSmart RNA Purification System with on-column tissue homogenizer kit (CM-61050, Denville Scientific). RNA quality and quantity was assessed by Nanodrop
absorbance at 260/280 (Thermo Scientific) and mRNA was reverse-transcribed using
High-Capacity cDNA Reverse Transcription Kit (Applied BioSystems). A total of 100ng
of cDNA was analyzed in a 20µL qRT-PCR reaction (TrueAmp SYBR Green, Smart
Bioscience, Inc.) with 300 nM of primers. Gene expression data were normalized to the
house keeping gene peptidylprolyl isomerase A (PPIA) using the 2-delta-delta C(T)
method (2-ΔΔCt) described by Livak and Schmittgen [172]. Sequences for primers
used for qRT-PCR are listed in Table 2.2.
Table 2.2 – Primer Sequences Used for qRT-PCR
Forward (5’-3’)
hIAPP Mouse Primers
mG6Pase
5’-CTGTCTGTCCCGGATCTACC-3’
mPEPCK
5’-AAGCGGATATGGTGGGAACT-3’
mPGC1-α
5’-ACGCGGACAGAATTGAGAGA-3’
mPPIA
5’-GGTCCTGGCATCTTGTCCAT-3’

Reverse (5’-3’)
5’-GCGCGAAACCAAACAAGAAG-3’
5’-CTGCGGCCAGGTATTTCTTC-3’
5’-GTTTCGTTCGACCTGCGTAA-3’
5’-ATGCCTTCTTTCACCTTCCCA-3’

ZDF Rat Primers
rG6Pase
rPEPCK
rPGC1-α
rPPIA

Forward (5’-3’)
5’-TGAATCACTTCCGGTCTCCTGTCC-3’
5’-GGGGTGCATGAAAGGCCGCA-3’
5’-GAGAGGCAGAAGCAGAAAGCAATTG-3’
5’-CGGCTGATGGCGAGCCCTTG-3’

Reverse (5’-3’)
5’-TCCCGATCCTTCCTTCTCTTCCTAG-3’
5’-ATCCGCATGCTGGCCACCAC-3’
5’-CATCATCCCGCAGATTTACGGTG-3’
5’-GCCAAATCCTTTCTCCCCAGTGC-3’

3.10.2 – In Vitro Gene Expression
Cells were washed with cold PBS after removal of media, lysed with direct
application of Tri reagent (Sigma) and placed on ice. Total RNA was extracted from cell
lysates, mRNA quality and quantity was assessed by Nanodrop absorbance at 260/280
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(Thermo Scientific) and mRNA was reverse-transcribed using High-Capacity cDNA
Reverse Transcription Kit (Applied BioSystems). Gene expression was analyzed by
semi-quantitative PCR using conditions optimized for each individual primer set. A total
100ng of cDNA, 10nM dNTPs (Denville), 1x Choice Taq (Denville) and 200 nM of genespecific primers (Integrated DNA Technologies, Inc.) were analyzed in a 20µL reaction
(MyCycler, Bio-Rad). Each primer was run for a specific number of cycles: PEPCK (23
cycles) and PPIA (23 cycles). Primers were designed to span exon junctions to
minimize signal from potential genomic DNA contamination. Final PCR products were
run on a 1.5% agarose gel (0.5µg/mL EtBr) in 1x TAE at 130mV for 80 minutes and
imaged with a ChemiDoc XRS (Bio-Rad). Band densities were analyzed using the
Image J software program and a specific sized selection box that limited the number of
pixels were analyzed. Gene expression data were normalized to the house keeping
gene PPIA. Primer sequences used for semi-quantitative PCR are listed in Table 2.3.
Table 2.3 – Primer Sequences Used for Semi-Quantitative PCR
Forward (5’-3’)
Reverse (5’-3’)
rPEPCK: 5’-GCAGGCTGGCTAAGGAGGAA-3’
5’-GGCCAGGTTGGTTTTCCCAC-3’
rPPIA:
5’-GTCGCGTCTGCTTCGAGCTGTTTG-3’ 5’-GTGTGAAGTCACCACCCTGGCACA-3’

3.11 – HOMA2-IR Analyses
Homeostatic Model Assessment 2 (HOMA2-IR) calculator was accessed on 30
June 2013 from: http://www.dtu.ox.ac.uk/index.php?maindoc=/homa/. HOMA2-IR is a
computer modeling program that calculates a corrected nonlinear estimation of insulin
resistance (IR) and percent beta-cell function (% β-cell function). A number of empirical
equations (nonlinear) are utilized by the HOMA2-IR computer program to predict
numerical values from paired fasting blood glucose and insulin samples. Paired fasting
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blood glucose and insulin measurements from weeks 0, 14, 26, 40 and 45 were
converted to mmol/L and pmol/L, respectively. Data are estimated numerical values for
the calculations of IR and % β-cell function.

3.12 – Statistical Analyses
Statistical analyses, given in detail in figure legends, were performed with
GraphPad Prism 5 and SPSS.

Data are presented as mean ± SEM.

significance between two groups was determined by unpaired t-test.

Statistical
Comparison

among groups was performed using two-way repeated measures ANOVA or two-way
mixed-design ANOVA and corrected for violation of sphericity with the GreenhouseGeisser epsilon.
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Chapter 4 – Dioxins
4.1 – Hypotheses and Aims of Dioxin Project
It is clear that dioxins are a persistent environmental contaminant with the ability
to influence glucose metabolism and possibly lead to alterations in diabetes
susceptibility.
Because of this possibility, the following hypotheses were formed: (1) Exposure
to dioxin alters hepatic gluconeogenic gene expression. (2) Dioxin-mediated AMPK
activation contributes to the suppression of hepatic glucose production. These
hypotheses were tested by two specific aims: (1) Characterize the effect of dioxin on
hepatic gluconeogenic gene expression. (2) Determine the molecular mechanism(s) by
which dioxins alter PEPCK gene expression.

4.2 – Characterize the Effect of Dioxin on Hepatic Gluconeogenic Gene
Expression
As described in the background section, dioxin exposure in humans has been
linked to changes in diabetes-related metabolic parameters [35, 36, 45, 138, 173].
However, its specific effect on hepatic glucose production (a key element in whole-body

Fig. 4.1 – Experimental paradigm utilized for all gene expression studies.
Cells were plated at t = -24 hours and changed to insulin-free media when 18 hour treatment was
begun at t = 0, 6 hour treatment was begun at t = 12 and 3 hour treatment was begun at t = 15.
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glucose homeostasis) is not clearly understood. To determine if dioxin affects
expression of the key genes involved in hepatic glucose production, primary rat
hepatocytes (PRH) and FAO rat hepatoma cells were treated with dioxin and mRNA
levels of gluconeogenic genes (PEPCK and G6Pase) were measured. Treatment times
(Figure 4.1) and doses were established in a series of pilot optimization experiments
(data not shown). As seen in Figure 4.2, 10nM dioxin was sufficient to suppress both
PEPCK and G6Pase by greater than 2-fold at 6 hours and by 4- and 10-fold
respectively at 18 hours over the 3 hour vehicle control. In contrast, expression of
CYP1A1 (a known AhR-regulated dioxin target gene) was strongly stimulated by dioxin
treatment, confirming the presence of dioxin in the cells (Figure 4.2). These results
demonstrate the ability of dioxin to suppress PEPCK and G6Pase, two key
gluconeogenic genes involved in hepatic glucose homeostasis. Results from FAO cells
(data not shown) mirrored those obtained from PRH cells.
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Fig. 4.2 – Dioxin exposure leads to increased suppression of both PEPCK and G6Pase
over time.
PRH cells in insulin-free media were exposed to DMSO or 10nM dioxin as well as 1µM dex
plus 1mM cAMP for 3, 6 and 18 hours and changes in gene expression were assessed by
qRT-PCR. Data analyzed by students T test and are the means +/- SEM of three
independent experiments, *p<0.05, **p<0.005.

4.3 – Determine the Molecular Mechanism by Which Dioxin Alters PEPCK Gene
Expression

4.3.1 – Effect of AhR Inhibition on Dioxin-Mediated PEPCK Gene Suppression
The effects of dioxin are primarily mediated by activation of the Aryl hydrocarbon
receptor (AhR) [48-54]. To determine if the dioxin-mediated suppression of PEPCK
gene expression is dependent on activation of AhR, a pharmacological antagonist of the
AhR, PD168641 (3’-methoxy-4-nitroflavone) was utilized [174, 175]. PRH cells were
pretreated with 1μM PD168641 for 15 minutes prior to addition of 1µM dex and 1mM
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cAMP and either DMSO or 10nM dioxin. Results demonstrated that PD168641
significantly inhibited the AhR at 24 hours, as evidenced by the nearly complete
suppression of the stimulatory effect of dioxin on CYP1A1 mRNA levels, in the presence
of PD168641 (Figure 4.3, right panel). In contrast, the suppression of PEPCK and
G6Pase gene expression was essentially unaffected by the presence of PD168641,
demonstrating that activation of the AhR was not the mechanism whereby dioxin
suppressed gluconeogenic gene expression.

Fig. 4.3 – Effect of AhR inhibition on dioxin-mediated suppression of PEPCK gene
expression.
PRH cells were pre-treated with PD 168641 (AhR antagonist) for 15 minutes. Cells were
then subjected to treatment groups consisting of: Vehicle = DMSO, Dioxin = 1mM cAMP +
1μM dex + 10nM dioxin, Dioxin + Antagonist = 1mM cAMP + 1μM dex + 10nM dioxin + 1µM
PD 168641 for 24 hours. Data are means of 2 independent experiments.

4.3.2 Dioxin is a Mild AMPK Activator
Most of the effects of dioxins are mediated by activation of the AhR. However,
my findings and a previous study have suggested an alternative mechanism whereby
dioxins may be suppressing PEPCK gene expression, via activation of AMPK [34].
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AMPK is activated by phosphorylation and is known to mediate a down regulation of
PEPCK gene expression [176, 177]. AMPK can be pharmacologically activated in PRH
and other hepatoma cell lines by the AMP analog, 5-aminoimidazole-4-carboxamide-1ß-D-ribofuranoside (AICAR) [178]. To determine if dioxin activates AMPK, (PRH) cells
were exposed to either 50nM dioxin or 500µM AICAR for 1, 2 and 4 hours (see Figure
4.4 for experimental time line) and then analyzed by western blot. Results demonstrated
that AMPK is phosphorylated and mildly activated in the presence of 50nM dioxin at 1, 2
and 4 hours (Figures 4.5 & 4.6). Secondarily, a downstream target of AMPK, Acetyl
CoA Carboxylase (ACC), is also phosphorylated in cells exposed to dioxin, causing it to
be inactivated [179].

These data demonstrate that dioxin activates AMPK, and

suggests that its effects on gluconeogenic gene expression are mediated by this
mechanism.

Fig. 4.4 – Experimental paradigm utilized for all protein expression studies.
Cells were plated at t = -24 hours and changed to insulin-free media two hours prior to beginning
dioxin exposure. Cells were treated with 1µM dex and 1mM cAMP and either 50nM dioxin or
500µM AICAR.
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Dioxin
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Fig. 4.5 – Dioxin is a mild AMPK activator.
Western blot showing changes in phosphorylation after dioxin or AICAR exposure.
PRH cells treated for 1, 2 and 4 hours with either 50nM dioxin or 500µM AICAR. pACC = phospho-ACC, t-ACC = total ACC, p-AMPK = phospho-AMPK, t-AMPK = total
AMPK.

44

Fig. 4.6 – Quantification of AMPK activation by dioxin.
AICAR is a known AMPK activator. PRH cells treated for 1,
2 and 4 hours with either 50nM dioxin or 500µM AICAR.
There is a “nearly significant” (p = 0.0505) stimulation by
dioxin observed at 2 hours. Data are the means +/- SEM of
three independent experiments.

4.4 – Conclusions
The effects of dioxins are primarily mediated by activation of the aryl hydrocarbon
receptor, AhR [48-54].

However, my data (figures 4.5 and 4.6) and a previously

published study have suggested an alternative mechanism whereby dioxin may be
suppressing PEPCK and G6Pase gene expression, via activation of AMPK [34]. AMPK
is a cellular energy-sensing protein that is activated when AMP levels within the cell
become high [141]. AMPK can be artificially activated in primary rat hepatocytes and
other hepatoma cell lines by the pharmacological reagent, 5-aminoimidazole-4carboxamide-1-ß -D-ribofuranoside (AICAR) resulting in AMPK phosphorylation. Acetyl
CoA Carboxylase (ACC) stimulates the conversion of Aceyl CoA to Malonyl CoA (MCA)
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which is a substrate for fatty acid (FA) synthesis and a potent inhibitor of the
mitochondrial

FA

transporter

carnitine

palmitoyltransferase

1

(CPT1)

[180].

Phosphorylated AMPK is known to phosphorylate and inactivate ACC, this leads to
decreased fatty acid synthesis.

Phosphorylated AMPK is also known to cause

suppression of PEPCK and G6Pase gene expression, which would reduce hepatic
glucose production [178]. Hepatic glucose production regulation by AMPK has been
attempted in the clinical setting with the anti-diabetic drug metformin [181, 182]; this
drug has been proposed to lower hepatic glucose production in diabetic patients via
AMPK activation [183, 184]. The ability of AMPK to suppress the key gluconeogenic
genes PEPCK and G6Pase demonstrates its importance as a regulator of hepatic
glucose production and as a potential or possible target of dioxin.
We observed that dioxin treatment stimulated the AMPK signaling pathway
(figures 4.5 and 4.6), which is known to have a suppressive effect on PEPCK gene
expression [178]. The pharmacological reagent Compound C (6-[4-(2-Piperidin-1-ylethoxy)-phenyl)]-3-pyridin-4-yl-pyrrazolo-[1,5-a]-pyrimidine) has been shown to inhibit
AMPK activation and could be utilized to ascertain if the suppressive effects of dioxin on
PEPCK and G6Pase gene expression are mediated via dioxin-induced AMPK
phosphorylation [182, 185].
Previously published studies suggested that while dioxin exposure increased
peripheral insulin resistance it did not appear to cause fasting hyperglycemia or
elevated hepatic glucose output [35, 39, 42, 45-47]. In concordance with these findings
we observed that dioxin treatment caused a strong suppression of the expression of
genes for the key gluconeogenic enzymes PEPCK and G6Pase (figures 4.2 and 4.3).
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However, the effects of dioxin in our in vitro system appear to be mediated
independently of the AhR (figure 4.3). There is a consensus among researchers that
dioxin-induced toxicity, while primarily mediated via the AhR, may function via an AhRindependent pathway [186-188]. A recently published study demonstrated the ability of
dioxin to suppress expression of the checkpoint protein Mad2 in AhR-deficient mice,
suggesting a novel dioxin-induced AhR-independent signaling mechanism at work
[189]. Additionally, AhR-independent effects of dioxin-induced toxicity include the ability
of dioxin to induce expression of several mouse glutathione S-transferase genes that do
not contain xenobiotic response elements (XREs), previously thought to be a necessity
in eliciting a dioxin response [190]. And several independent studies have shown that
dioxin targets T cells via both AhR-dependent and AhR-independent mechanisms
resulting in suppression of the immune system [191-196].
While the effects on hepatic glucose production, AMPK and energy metabolism
are not clearly understood, previous studies and my data suggest that, in addition to
interacting with its well-characterized receptor AhR, dioxin may function in an AhRindependent manner to target and activate the metabolic kinase, AMPK.

AMPK

regulates a variety of metabolic pathways and its activation by an environmental
toxicant would constitute a mechanistic link between toxicant exposure and the
regulation of metabolism.
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Chapter 5 – Lead Exposure Promotes Diabetes Development in Obese
Rats

As described in the background section, little recent work addresses the effect of
Pb on metabolic parameters in vivo. The data that do exist, when taken together,
suggest that Pb exposure alters liver function, hepatic gluconeogenic gene expression
and glycemia [152-154].

However, they do not address the potential pathological

interactions between Pb exposure and concomitant risk factors such as obesity, which
is strongly associated with diabetes and the metabolic syndrome [44]. The Pb-obesity
interaction is a relevant issue in large sections of the US population where
environmental stressors of over-nutrition (taking in more calories than the body needs)
and an inactive or sedentary lifestyle are common and co-exist with exposure to
persistent environmental toxicants, such as Pb.
The overall goal of the in vivo portion of my PhD work is to characterize the effect
of Pb exposure on diabetes risk in metabolically stressed (obese) rodents. To explore
the specific hypothesis that Pb exposure increases diabetes susceptibility in obese
individuals, two well-established rodent models of obesity were utilized: the Zucker
Diabetic Fatty (ZDF) rat and the high fat fed, human islet amyloid polypeptide (hIAPP),
transgenic mouse (presented in Chapter 6). The experimental approach is designed to
reproduce, as far as possible, effects of Pb exposure in the human population, where
obesity and diabetes risk factors are common.
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5.1 – Zucker Diabetic Fatty (ZDF) Rat Model
One of the standard rodent models used in diabetes research to study the
physiology of obesity-related type 2 diabetes is the Zucker Diabetic Fatty (ZDF) rat.
Originally derived from a colony of rats at Eli Lilly Research Laboratories and named
after the scientists that discovered the fatty mutation, the ZDF (fa/fa) rat was established
from a colony that had the diabetic characteristics of obesity and fasting hyperglycemia
[197]. The genetic lesion that causes hyperphagia and obesity in ZDF rats is a mutation
in the leptin receptor. Rats homozygous for this mutation (fa/fa) will become obese
when fed regular chow. A specially formulated high fat diet leads to development of
Type 2 diabetes in fa/fa animals. ZDF rats that are heterozygous (fa/+) tend to be lean
and are often utilized as a non-diabetic control.
The diabetes phenotype differs in male vs. female ZDF rats. There are several
advantages in utilizing female ZDF rats instead of the more commonly used male ZDF
rats. Feeding commercially available rodent diets, such as Purina 5008, to female ZDF
rats induces a prolonged insulin resistant but non-diabetic state. However, when fed
the RD13004 high fat diet from Research Diets, Inc., they develop fulminate diabetes
within approximately 1 month [198].

The progression of the female ZDF toward

fulminate diabetes on the RD13004 diet is very well characterized and highly
reproducible.
Unlike the male ZDF, the female possesses more robust β-cell compensation
even though they share similar levels of insulin resistance. The β-cell compensation
allows for maintenance of blood insulin levels for a much longer time frame and extends
the time course of diabetes development. They can be initiated into this progressive
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pathway at 6 weeks and be maintained in this insulin resistant state for up to 25 weeks
of age. This large span of time provides an extended period in which these animals are
obese, insulin resistant and non-diabetic, providing an excellent opportunity to observe
subtle effects of Pb exposure on the rate of diabetes progression during the
experimental time frame (Figure 5.1).

Fig. 5.1 – Experimental time frame for ZDF rats.
Rats arrived and were allowed to acclimate for one week. Weekly fasting blood
glucose draws and monthly oral glucose tolerance tests (OGTTs) were performed as
indicated. RD13004 high fat diet feeding was initiated at 20 weeks.

5.2 – ZDF Experimental Setup
The ZDF experiment consisted of two groups (n=4) of 6 week old female fa/fa
rats, the characteristics of which were described in the previous paragraphs.

Rats

arrived and were allowed one week to acclimate prior to initiation of experimental
protocols. One group was provided 0.05% w/v Pb acetate (PbAc) in drinking water (an
amount previously determined to generate a blood lead level of approximately 40-50
μg/dL in rats [154]). The control group was provided an equimolar amount of NaAc in
drinking water to balance the acetate intake of the two groups. Animals were fed a
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standard chow diet (Purina 5008) until week 20, when they were switched to the
RD13004 high fat diet (45% calories from fat diet) from Research Diets, Inc. Food and
water were offered ad lib.
Body weight and food intake were measured weekly, blood was drawn weekly
from fasted animals for blood glucose level determination. Oral glucose tolerance tests
(OGTTs) were performed every 4 weeks. After 25 weeks of exposure, animals were
sacrificed by CO2 asphyxiation and exsanguination via aortic puncture. Immediately
preceding termination, rats were fasted for 6 hours and then allowed a 2 hour re-feeding
period. Pancreatic and liver tissues were removed and portions were placed in 4%
buffered formalin at 4ºC, flash-frozen or frozen in OTC for histology and molecular
analyses. Additional endpoint measures included plasma insulin and liver triglycerides.

5.3 – Basic Parameters of the ZDF Model
Pb exposure did not affect body weight (Figure 5.2) or food intake (Figure 5.3).
To assess blood Pb levels generated by 0.05% w/v PbAc in drinking water (an amount
previously determined to generate a blood lead level of approximately 40-50 μg/dL in
rats [154]), Pb levels in packed red blood cells were measured by atomic absorption
spectrometry at Detroit Medical Center – University Laboratories. The average blood
Pb level of the Pb-treated rats, at termination, was determined to be 49µg/dL (Figure
5.4).

The findings that there were no body weight or food intake differences suggest

that there were no major effects of Pb on appetite or activity even at relatively high
levels of exposure.
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Fig. 5.2 – Body weight measures for ZDF rats.
There was no difference in body weight between groups. Data are means
+/- SEM, weeks 0-8: both groups n=4, Weeks 9-25: Na n=4, Pb n=3.

Fig. 5.3 – Food consumption measures for ZDF rats.
There was no difference in food consumption between groups. Data are
means, +/- SEM, weeks 0-8: both groups n=4, Weeks 9-25: Na n=4, Pb n=3.
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Fig. 5.4 – Blood Pb levels for ZDF rats at termination.
ZDF rats treated with 0.05% w/v PbAc or equimolar NaAc
in drinking water. Termination BLL average was 49µg/dL.
Analysis completed by students T test. Data are means
with SEM, * p<0.05, Na n=4, Pb n=3.

5.4 – Pb Exposure Effects on Metabolic Parameters
Elevated fasting blood glucose is one of the hallmarks of type 2 diabetes.
Although female ZDF fa/fa rats fed a chow diet develop insulin resistance, they are able
to maintain relatively normal blood glucose levels due to efficient compensation of
insulin output by the endocrine pancreas. However, as shown in Fig. 5.5, exposure to
Pb induced a persistent fasting hyperglycemia starting at 10 weeks exposure, compared
to control rats who maintained near normal levels of fasting blood glucose throughout
the study.

Repeated measures ANOVA calculations demonstrated a significant

deviation in fasting blood glucose levels between the Pb and control groups beginning
at 8 weeks of exposure through termination.
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Fig. 5.5 – Pb exposure causes fasting hyperglycemia in obese rats.
The Pb group started with lower fasting glucose levels (due to chance), but from week 8,
their glucose levels rose above the control group. The high fat diet uncovers an elevated
susceptibility to diabetes in the Pb group. Analysis completed by repeated measures
ANOVA and corrected for violation of sphericity with the Greenhouse-Geisser epsilon
demonstrated significant hyperglycemia in Pb group from week 8 through termination. Data
are means +/- SEM, *p<0.05, weeks 0-8: both groups n=4, Weeks 9-25: Na n=4, Pb n=3.

Another hallmark of diabetes is glucose intolerance, the inability to clear
postprandial glucose from the circulation. Monthly OGTTs performed after an overnight
fast showed a striking progressive glucose intolerance in Pb-exposed rats, but not in
control rats (Figures 5.6 and 5.7). The fasting hyperglycemia and glucose intolerance
observed in the Pb treated animals clearly demonstrates that Pb exposure has a
profound negative effect on glucose homeostasis in obese rats. There are multiple
mechanistic possibilities for how Pb might alter glucose metabolism, including reduced
peripheral insulin sensitivity, defective glucose-mediated insulin secretion by the
pancreas, and/or elevated hepatic glucose production.
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Fig. 5.6 – Pb exposure causes glucose intolerance.
Oral glucose tolerance tests (OGTTs) in control (NaAc) and Pb-treated (PbAc) female ZDF
fa/fa rats after exposure to Pb for 0 or 16 weeks. Both groups had similar glucose tolerance
before Pb exposure, while at 16 weeks, the Pb exposed rats were glucose intolerant
compared to control rats. Glucose tolerance at 16 weeks was significantly different by
ANOVA, **p<0.005. Data are means, +/- SEM, before Pb exposure: n=4 both groups, 16
Weeks: Na n=4, Pb n=3.

Fig. 5.7 – Progressive glucose intolerance caused by Pb exposure.
The area under the curve (AUC) was calculated for each of the OGTT assays
performed on the ZDF rats. The data shows a progressive glucose intolerance in the
Pb exposed rats, while the control rats maintained a similar glucose tolerance
throughout the course of the study. Data are means, weeks 0-8: both groups n=4,
weeks 12-20: Na n=4, Pb n=3.
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To examine the possibility that Pb directly affects regulation of glucose
production in the liver, changes in hepatic gluconeogenic gene expression in ZDF rats
was examined. Upon termination, mRNA was isolated from a small sample of flashfrozen liver tissue. Changes in gluconeogenic gene expression were quantified by twostep qRT-PCR with sequence-specific primers for PEPCK, PGC1-α and PPIA.

As

shown in Fig 5.8, these data revealed that expression of the hepatic PEPCK gene was
elevated in Pb-exposed animals.

Elevated PGC1-α mRNA is consistent with the

PEPCK results as PGC1-α functions as a transcriptional co-activator for this gene.
Overall, the gene expression results are consistent with the possibility that the fasting
hyperglycemia observed in the Pb-exposed animals is due, at least in part, to
abnormally elevated hepatic glucose output. It is important to note that the animals
were sacrificed at termination after a fasting re-feeding protocol (described in methods),
so that in this context, the elevated gluconeogenic gene expression could be related, at
least in part, to a deficiency in the insulin-mediated suppression of gluconeogenic gene
expression.
resistance.

In other words, these findings may be indicative of hepatic insulin
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Fig. 5.8 – Pb exposure induces gluconeogenic gene expression.
Changes in gluconeogenic gene (mRNA) expression were quantified by qRTPCR with sequence-specific primers for PEPCK and PGC1-α. Data are means
relative to housekeeping gene PPIA +/- SEM, presented on a log axis, Na n=4,
Pb n=3.

To examine the possibility that Pb exposure affects pancreatic insulin production,
insulin levels were determined in plasma samples from multiple time points throughout
the study. Insulin ELISA results from the ZDF rats show a mild decrease in blood
insulin levels in the Pb-treated rats from approximately 8 weeks of treatment through
termination (Figure 5.9). While these findings are consistent with a potential defect in
the ability of the pancreas to produce insulin, the differences between the control and
treated groups were small and not statistically significant. Insulin ELISA results from
fasting/re-feeding termination samples showed no difference between the control and
treated groups (data not shown). Together these findings indicate that while there may
be some pancreatic deficiency relative to the control group, Pb exposure did not cause
pancreatic failure or a major defect in the ability of islets to produce insulin.
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Fig. 5.9 – Pb exposure does not affect insulin
production.
Plasma insulin levels measured by ELISA show
decreased levels in Pb-treated rats from approximately
week 8 forward. Data are means +/- SEM, Weeks 0-8:
both groups n=4, Weeks 12-20: Na n=4, Pb n=3.

A small sample of flash-frozen liver tissue was ground and analyzed for
triglyceride content by colorimetric ELISA assay to determine lipid content. Results
revealed that the Pb-treated ZDF rats had accumulated significantly more triglycerides
in their liver than the control animals (Figure 5.10). The data demonstrates that Pb
exposure promotes accumulation of triglycerides within the liver tissue consistent with
the development of hepatic steatosis.
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Fig. 5.10 – Pb exposure causes increased triglyceride
accumulation. Liver tissue triglycerides were measured
by colorimetric assay.
Data are means +/- SEM,
analyzed by students t test, **p < 0.005, Na n=4, Pb n=3.

5.5 – Pb Exposure Effects on Histological Parameters
To determine if Pb exposure affected liver morphology, a portion of the liver from
each animal was subjected to standard histological analyses. Hematoxylin and eosin
(H & E) staining demonstrated that both control and Pb-treated rats have normal hepatic
lobule structure (Figures 5.11 and 5.12), showing that Pb does not affect gross liver
morphology.
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Fig. 5.11 – Control ZDF Liver H & E.
Normal hepatic lobular structure is intact. Magnification 5x, bar = 1mm.

Fig. 5.12 – Pb-treated ZDF Liver H & E.
Normal hepatic lobular structure is intact. Magnification 5x, bar = 1mm.
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Having determined that Pb exposure did not alter hepatic morphology, I sought to
determine if it had any effect on glycogen content or distribution. Periodic Acid-Schiff
stain is commonly utilized to detect glycogen in histological sections. A specimen that is
PAS-positive will show glycogen (carbohydrates) as pink/magenta to purple/red in color.
PAS staining of prepared liver slides, while not quantitative, revealed that Pb exposure
caused a generalized depletion of hepatic glycogen, as evidenced by the decreased
level of PAS-positive staining in the Pb-treated liver slide (Figures 5.13 and 5.14).
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Fig. 5.13 – Control ZDF Liver PAS.
Note the numerous PAS-positive glycogen deposits (purple coloration) in the
liver of the control rat. Magnification 5x, bar = 1mm.

Fig. 5.14 – Pb-Treated ZDF Liver PAS.
Evidence of glycogen depletion after Pb exposure. Note the decrease in PASpositive staining in the liver of the Pb-treated rat. Magnification 5x, bar = 1mm.
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To determine if Pb exposure affected pancreatic morphology, a portion of the
pancreas from each animal was subjected to standard histological analyses. While the
quality of the specimens was not ideal due to the embedding technique utilized, H & E
staining demonstrated that Pb exposure did have an effect on islet morphology. Islets
from control rats (n = 4) appeared normal, with a round shape and a well-defined border
(Figure 5.15). However, islets from Pb-treated rats (n = 3) appeared to be somewhat
larger in size and did not display a well-defined border (Figure 5.16). Overall, the
subjective appearance of the islets from the Pb exposed animals suggested a general
degradation of normal islet architecture, which is consistent with the possibility that
these islets have at least a minor degree of compromised endocrinological function.
Staining for specific hormones was not an option due to the poor quality of the
specimens.
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Fig. 5.15 – Control ZDF Pancreas H & E.
Islets are lighter stained, round areas, denoted by the red arrows. Control
animal islet physiology appears normal. Magnification 5x, bar = 1mm.

Fig. 5.16 – Pb-Treated ZDF Pancreas H&E.
Islets are lighter stained areas, denoted by the red arrows. Note perimeter
changes and damaged architecture of islets in Pb-treated animal, this islet
physiology appears abnormal. Magnification 5x, bar = 1mm.
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Noting the alterations in islet morphology in Pb-treated animals, I wanted to
determine if Pb exposure caused an increased presence of β-cells in pancreatic islets.
Aldehyde Fuchsin is commonly used to distinguish β-cells from α-cells and δ-cells within
the islets of pancreatic tissue samples as β-cells stain a blue to violet or purple punctate
in color. Although these specimens are not ideal, and therefore the β-cells are not
easily quantified, there appeared to be increased Aldehyde Fuchsin staining in Pb
exposed samples (Figures 5.17 and 5.18).

These findings, while not striking, are

suggestive of β-cell hyperplasia in the Pb-treated animals and are consistent with the
apparent larger size of islets observed in the H&E stained sections.
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Fig. 5.17 – Control ZDF Pancreas Aldehyde Fuchsin.
Yellow arrows indicate Aldehyde Fuchsin-positive β-cells. Magnification 10x,
bar = 200µm.

Fig. 5.18 – Pb-Treated ZDF Pancreas Aldehyde Fuchsin.
The appearance of a greater number of Aldehyde Fuchsin-positive β-cells
(yellow arrows) is suggestive of a greater degree of β-cell hyperplasia in the
Pb-treated animals. Magnification 10x, bar =200µm.
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5.6 – Additional Histological Observations
Liver tissue was examined for fibrosis with Masson’s Trichrome stain, but there
was no discernible difference between the control and Pb-treated animals (data not
shown). Pancreatic tissue was also examined for fibrosis with Masson’s Trichrome
Stain, and while there was some fibrosis present, there was no discernible difference in
the degree of fibrosis between the control and Pb-treated groups (data not shown).

5.7 – Discussion of ZDF Study
It is clear from the data presented here, that Pb exposure promotes the
development of diabetes in obese rats, specifically causing the development of fasting
hyperglycemia and glucose intolerance. Of additional interest is the observation that
when the animals were switched to a diabetogenic high fat diet at week 20 the Pbexposed rats showed a dramatic increase in fasting hyperglycemia, suggesting that
extended exposure to the toxicant made the animals more susceptible to the deleterious
effects of the further metabolic stress of a high fat diet. These striking findings provide
strong support for the hypothesis that, in metabolically stressed rodents, Pb exposure
increases susceptibility to diabetes and promotes the progressive development of
metabolic abnormalities.
Although many factors can contribute to fasting hyperglycemia, a major
contributor is often elevated hepatic glucose output [199, 200]. In accordance with the
possibility that Pb directly affects the regulation of glucose production in the liver, gene
expression data revealed that PEPCK and PGC1-α expression were elevated in Pbexposed animals. These findings at the mRNA level are consistent with previously
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published results from somewhat similar experiments with Pb exposed rats elevated
activity levels of PEPCK were observed (described in more detail in the background
section) [152-154]. The dysregulation of the insulin-mediated suppression of hepatic
gluconeogenic gene expression could be a major contributor to the glucose intolerance
observed in this animal study and suggests hepatic insulin resistance.
Consistent with this possibility is the observation of hepatic steatosis in the Pbtreated animals.

Fatty liver is frequently observed in insulin resistant humans and

animal models and is associated specifically with hepatic insulin resistance [201-203].
The hepatic lipid accumulation in our animals may be secondary to the hyperglycemia
we observed, which has been shown to be a “trigger” that stimulates de novo synthesis
of hepatic lipids [204, 205].

Also consistent with Pb-induced metabolic dysfunction

centered on the liver, is the observation that livers from Pb exposed rats were glycogen
depleted (Figures 5.13 and 5.14).

Glycogen depletion has been associated with

elevated fasting blood glucose [200, 206], and may also be consistent with hepatic
insulin resistance.
Examination of gross pancreatic morphology using H & E staining revealed Pbrelated disturbances in islet organization. Control rat islets appeared normal, with a
round shape and a reasonably definable border. Pb-treated rat islets lacked the round
shape seen in the control animals and had less well defined borders.

Although

suggestive of pancreatic dysfunction, we did not observe a significant difference in
blood insulin levels suggesting that these abnormalities were not severe enough to
block β-cell compensation in these animals.

Beta-cell compensation in Pb-treated

animals was confirmed by a greater prevalence of Aldehyde Fuchsin positive β-cells.
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Our results do not rule out the possibility that Pb affects peripheral insulin
resistance in these animals. Unfortunately, a direct measurement of peripheral insulin
sensitivity in intact animals is difficult and was beyond the technical scope of our lab and
my thesis. If there is peripheral insulin resistance in these animals, it would contribute
to the observed hyperglycemia, which was present despite normal insulin levels.
These data demonstrate for the first time that Pb promotes the development of
Type 2 diabetes in a rat model of obesity.

I identified Pb-induced defects in both

hepatic glucose output and in postprandial glucose clearance. Both of these are insulin
mediated processes and it seems likely that Pb is interfering in the insulin signaling
pathway, at least in liver, and possibly also in muscle. The data also identified key
histological aspects of Pb-exposure, including islet abnormalities and increased β-cell
compensation.
A key question that the data do not address is if the pro-diabetic effect of Pb is
dependent on obesity or other metabolic stresses. The experiments conducted in the
hIAPP transgenic mouse model (described in the next chapter) were designed to
examine this possibility and to characterize the specific effects of Pb exposure in a high
fat diet-induced rodent model of Type 2 diabetes. The gene expression results are
consistent with previously published animal studies and yield a potential molecular
mechanism to be explored in vitro (described in Chapter 7).
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Chapter 6 – Lead Exposure Causes Metabolic Abnormalities in a
Humanized Mouse Model of Pancreatic Amyloidosis

The Pb-obesity interaction is a relevant issue in large sections of the US
population where environmental stressors of over-nutrition and an inactive sedentary
lifestyle are common, and co-exist with exposure to persistent environmental toxicants,
such as Pb.
The overall goal of the in vivo portion of my PhD work is to characterize the effect
of Pb exposure on diabetes risk in metabolically stressed (obese) rodents. To explore
the specific hypothesis that Pb exposure increases diabetes susceptibility in obese
individuals, two well-established rodent models of obesity were utilized: the Zucker
Diabetic Fatty (ZDF) rat (presented in Chapter 5) and the high fat fed, human islet
amyloid polypeptide (hIAPP), transgenic mouse, presented in the current chapter. The
experimental approach for the animal studies is designed to reproduce the effects of Pb
exposure in the human population, where obesity and diabetes risk factors are
common.

6.1 – human Islet Amyloid Polypeptide (hIAPP) Mouse Model
In contrast to the ZDF rat, which possesses a genetic predisposition to obesity
and diabetes due to hyperphagia, the hIAPP mouse is a high fat diet-induced transgenic
rodent model that expresses the human islet amyloid polypeptide gene. The hIAPP
transgenic mouse was created to mimic a common pathophysiology of human Type 2
diabetes, pancreatic amyloidosis [207, 208]. Amyloid deposits accumulate in pancreatic
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islets in the vast majority of people with type 2 diabetes. Amyloid is produced by β-cells
of the islets and is co-secreted with insulin in response to changes in blood glucose
[209-211]. And accumulation of amyloid plaques in pancreatic islets is associated with
the progression of diabetes, including characteristic loss of beta-cell mass and function
[207, 208]. The amyloid deposits that form in the pancreas are generated specifically
from a pancreatic-specific amyloid called islet amyloid polypeptide (IAPP).

The

amyloidogenic potential of IAPP is dependent on the sequence of the peptide, and the
sequence of the protein produced in humans, non-human primates and cats is of the
amyloidogenic form. The sequence of the gene in most rodents, including mice, is
different and produces an islet amyloid protein that does not form plaques [212, 213].
Because rodent IAPP is non-amyloidogenic, they do not experience the same amyloiddependent pancreatic dysfunction observed in humans, even in the face of similar
metabolic stresses (i.e. peripheral insulin resistance). Creation of hIAPP transgenic
rodents allowed for expression of the human IAPP gene and amyloid aggregation &
deposition in the pancreas under certain dietary conditions [169, 214].
The hIAPP transgenic mouse strain is maintained in a C57Bl6 background [215217]. This mouse expresses the transgene specifically in beta cells (under the control
of the rat INS2 promoter) but apparently does not develop diabetes, hyperglycemia or a
pancreatic insufficiency [214]. However, when the hIAPP transgene is expressed in
C57Bl6/DBA-2 F1 mice, pancreatic amyloid deposition and an elevated susceptibility to
Type 2 diabetes occurs. Previous studies observed a negative influence of estrogen on
expression of the hIAPP transgene [169, 170], so only male C57Bl6/DBA-2 F1 hIAPPheterozygous transgenic mice were used in our study.
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Because previously published data demonstrated that hIAPP transgenic mice
required a minimum of 12 months on a high fat diet to develop pancreatic amyloid
plaques, the experimental time frame for the hIAPP transgenic mice was lengthened
from that of the ZDF rats (See Figure 6.1) [215]. This also allowed an extended period
to observe what may be subtle effects of Pb exposure on the rate of diabetes
progression.

6.2 – hIAPP Experimental Setup
Four groups of male hIAPP mice were established (the characteristics of which
were described in the previous paragraphs). Amounts of PbAc utilized in the hIAPP
transgenic mouse study were based on previously published data [154], and the blood
lead levels generated in my own ZDF rat experiment described above. Two groups

Fig. 6.1 – Experimental time line for hIAPP Mice.
At 10 weeks of age, mice were placed on the high fat diet and treatment with Pb was initiated. Biweekly fasting blood glucose draws and bi-annual OGTTs were performed as shown above. Both high
dose groups (n=16), both low dose groups (n=12).
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(n=16) were treated with 0.02% w/v PbAc (“high treated”) or equimolar NaAc (“high
control”) in the drinking water. The other two groups (n=12) were treated with 0.005%
w/v PbAc (“low treated”) or equimolar NaAc (“low control”) in the drinking water. Male
heterozygous hIAPP transgenic mice were started on the feeding/exposure protocol at
10 weeks of age.

All animals were fed a standard chow diet (Purina 5009) until

weaned, then placed on a high fat chow diet (Autoclavable Mouse Breeder Diet 5021,
Purina) containing 9% fat w/w, (45% calories from fat) through termination (week 45 of
the study, 55 weeks of age). Food and water were offered ad lib.
Body weights and food consumption were measured weekly; blood was drawn
bi-weekly from fasted animals for blood glucose level determination.

Oral glucose

tolerance tests (OGTTs) were performed before the initiation of treatment to establish
baseline, and then repeated at 26 weeks and 40 weeks of treatment to look for changes
in glucose tolerance. After 45 weeks of exposure, animals were sacrificed following an
8 hour fast by CO2 asphyxiation followed by cervical dislocation and exsanguination by
cardiac puncture. Relevant tissues were removed and portions placed in 4% buffered
formalin at 4°C, freeze-clamped in liquid nitrogen or frozen in OTC for histological and
molecular analyses. Additional endpoint measures included plasma insulin and liver
triglycerides.

6.3 – Basic Parameters of the hIAPP Transgenic Model
Pb exposure did not affect body weight (Figures 6.2 and 6.3) or food intake
(Figures 6.4 and 6.5). Blood lead levels were assessed by ICP-MS at Wayne State
University School of Medicine’s Biochemistry Department (See Chapter 3 for protocol).
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The average blood lead levels for the high treated animals, exposed to 0.02% w/v
PbAc, was 41.5 μg/dL at termination (Figure 6.6). The average blood lead levels for the
low treated animals, exposed to 0.005% w/v PbAc, was 21.5 μg/dL at termination
(Figure 6.7). The lack of significant differences in body weight or food intake suggests
that there were no major effects of Pb on appetite or activity with these levels of
exposure.
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Figure 6.2 – Body weight measures for hIAPP high dose (0.02% w/v) group.
Data are means +/- SEM. High control: Weeks 0-16 n=11, weeks 17-34 n=15, weeks 35-40
n=13, weeks 41-43 n=12, weeks 44-45 n=11. High treated: Weeks 0-20 n=16, weeks 21-28
n=15, weeks 29-44 n=14, weeks 44-45 n=13.

Figure 6.3 – Body weight measures for hIAPP low dose (0.005% w/v) group.
Data are means +/- SEM. Low control: Weeks 0-21 n=12, weeks 22-23 n=11, weeks 24-29
n=10, weeks 30-35 n=9, weeks 36-40 n=8, weeks 41-45 n=7. Low treated: Weeks 0-16
n=12, weeks 17-42 n=11, weeks 43-44 n=10, weeks 44-45 n=8.
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Fig. 6.4 – Food consumption measures for hIAPP high dose (0.02% w/v) group.
High control: Weeks 0-16 n=11, weeks 17-34 n=15, weeks 35-40 n=13, weeks 41-43 n=12,
weeks 44-45 n=11. High treated: Weeks 0-20 n=16, weeks 21-28 n=15, weeks 29-44 n=14,
weeks 44-45 n=13. Data are means +/- SEM.

Fig. 6.5 – Food consumption measures for hIAPP low dose (0.005% w/v) group.
Data are means +/- SEM. Low control: Weeks 0-21 n=12, weeks 22-23 n=11, weeks 24-29
n=10, weeks 30-35 n=9, weeks 36-40 n=8, weeks 41-45 n=7. Low treated: Weeks 0-16
n=12, weeks 17-42 n=11, weeks 43-44 n=10, weeks 44-45 n=8.
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Fig. 6.6 – Blood Pb levels at termination of hIAPP high dose (0.02%
w/v) group. Analysis completed by students T test. Data are means
with SEM, high control n=11, high treated n =13. *** p < 0.0002.

Fig. 6.7 – Blood Pb levels at termination of hIAPP low dose (0.005%
w/v) group. Analysis completed by students T test. Data are means
with SEM, low control n=7, low treated n =8. **** p < 0.0001
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6.4 – Pb Effects on Metabolic Parameters in hIAPP Transgenic Mice
An elevation in fasting blood glucose is a characteristic of Type 2 diabetes.
Because the hIAPP transgenic mice were bred on to a DBA/2 background, they had a
predisposition to develop insulin resistance, but are able to retain relatively normal
blood glucose levels due to insulin hypersecretion in response to elevated blood
glucose levels [218].

As shown in Figures 6.8 and 6.9, Pb exposure induced a

persistent fasting hyperglycemia from 8 weeks of treatment, in both the high and low
exposure groups as compared to the near-normal fasting blood glucose levels
throughout the study of both control groups.
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Fig. 6.8 – Fasting blood glucose measures for hIAPP high dose (0.02% w/v) group.
Both groups began with normal fasting blood glucose levels (due to chance), but from week 8,
the Pb-treated (high treated) group rose above the high control group. Analyses by students
T test, data are means +/- SEM. *p<0.05, **p<0.005, ****p<0.0001.
High control: Weeks 0-16 n=11, weeks 17-34 n=15, weeks 35-40 n=13, weeks 41-43 n=12,
weeks 44-45 n=11.
High treated: Weeks 0-20 n=16, weeks 21-28 n=15, weeks 29-44 n=14, weeks 44-45 n=13.

Fig. 6.9 – Fasting blood glucose measures for hIAPP low dose (0.005% w/v) group.
Both groups began with normal fasting blood glucose levels (due to chance), but from week 4,
the Pb-treated (low treated) group rose above the low control group. Analyses by students T
test, data are means +/- SEM. * p<0.05, ** p<0.005, *** p<0.0005
Low control: Weeks 0-21 n=12, weeks 22-23 n=11, weeks 24-29 n=10, weeks 30-35 n=9,
weeks 36-40 n=8, weeks 41-45 n=7.
Low treated: Weeks 0-16 n=12, weeks 17-42 n=11, weeks 43-44 n=10, weeks 44-45 n=8.
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Glucose intolerance, the inability to clear postprandial glucose from the
circulation, is another characteristic of diabetes.

Complete OGTTs were performed

after an 8 hour fast to establish a baseline (Time 0) and repeated at 26 weeks of
treatment to observe changes in glucose tolerance. Glucose tolerance was similar in all
groups before the initiation of Pb exposure, but after 26 weeks of Pb exposure, the high
dose group was more glucose intolerant compared to the controls, (Figure 6.10). The
low dose group behaved similarly; after 26 weeks of exposure, the Pb-treated group
was glucose intolerant compared to the low control group although this difference did
not achieve statistical significance (Figure 6.11).
The increased glucose intolerance in the low dose animals is more clearly
visualized when the data are rearranged to directly compare, the effect of time on
glucose tolerance within a single treatment group. OGTT data of the low control at 0
and 26 weeks were plotted on one graph, while the same was done for the low treated
(Figure 6.12). When viewed in this manner it is clear that 6 months of Pb exposure
induced glucose intolerance. The fasting hyperglycemia and glucose intolerance
observed in both the high and low Pb-treated mice resembles that seen in the ZDF rats
and further supports the idea that Pb exposure has a profound negative effect on
glucose homeostasis in metabolically stressed rodents. As stated previously, there are
multiple mechanistic possibilities for how Pb might alter glucose metabolism, including
reduced peripheral insulin sensitivity, defective glucose-mediated insulin secretion by
the pancreas, and/or elevated hepatic glucose production.
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Fig. 6.10 – Pb exposure causes glucose intolerance in
high dose group.
Oral glucose tolerance tests in hIAPP high treated (0.02% w/v)
or high control after exposure to Pb for 0 or 26 weeks. The
OGTT curves from the baseline measure are not different,
while at 26 weeks, the high Pb-treated group is glucose
intolerant compared to the high control group. Time and
treatment had an effect on glucose tolerance at 26 weeks as
determined by ANOVA, *p<0.01. Data are means +/- SEM.
Baseline: n=16 both groups. 26 weeks: n=15 both groups.
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Fig. 6.11 – Pb exposure causes glucose intolerance in low
dose group.
Oral glucose tolerance tests in hIAPP low treated (0.02% w/v)
or low control after exposure to Pb for 0 or 26 weeks. The
OGTT curves from the baseline differ only at 30 minutes
(*p<0.01), while at 26 weeks, the low Pb-treated group is
glucose intolerant compared to the low control group. Data are
means +/- SEM. Baseline: n=12 both groups. 26 Weeks: low
control n=10, low treated n=11.
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Fig. 6.12 – Data rearranged for direct comparison of effect of time on
glucose tolerance.
Oral glucose tolerance tests in hIAPP low treated (0.02% w/v) or low
control after exposure to Pb for 0 or 26 weeks. Time of treatment had an
effect on glucose tolerance at 26 weeks in the Pb treated group (*p<0.01)
as demonstrated by ANOVA. Data are means +/- SEM. Baseline: n=12
both groups. 26 Weeks: low control n=10, low treated n=11.

83
To examine the possibility that Pb directly affects regulation of glucose
production in the liver, changes in hepatic gluconeogenic gene expression in hIAPP
transgenic mice were examined. Upon termination, mRNA was isolated from a small
sample of flash-frozen liver tissue. Changes in gluconeogenic gene expression were
quantified by two-step qRT-PCR with sequence-specific primers for PEPCK, G6Pase,
PGC1-α and PPIA. These data showed that there was no significant difference in
expression of any genes between Pb-exposed or control animals in either the high or
low dose groups (Figures 6.13). The gene expression results from the hIAPP mice
differ from those observed in the ZDF rats. However, this is consistent with previously
published data demonstrating that DBA/2 mice respond to elevated glucose by
compensatory hypersecretion of insulin, and have been shown to have higher than
normal plasma insulin levels during a fast, which could reduce hepatic gene expression
levels [218]. A significant difference between the ZDF rat experiment and the mouse
experiment, in this regard, was that the rats were sacrificed at termination after a fasting
re-feeding protocol (described in methods), while the hIAPP mice were sacrificed after
an 8 hour fasting-only protocol.
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Fig. 6.13 – Pb exposure does not affect gluconeogenic gene expression in hIAPP mice.
No changes in gluconeogenic gene (mRNA) expression were observed in either the high or low
dose groups. Gene expression for PEPCK, G6Pase, PGC1α and PPIA was quantified by qRTPCR. Data are means with SEM relative to PPIA. High control n=11, high treated n=13, low
control n=7, low treated n=8.
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To examine the effects of Pb exposure on pancreatic insulin production, insulin
levels were determined in plasma samples from multiple time points throughout the
study. There was also an assessment of insulin levels during the 9 month OGTT at
both the 0 and 60 minute time points. Insulin ELISA results from the hIAPP mice did not
show differences between Pb and control groups.

All groups displayed increasing

insulin levels until week 40, when insulin levels decreased (Figure 6.14). The insulin
ELISA results from the 40 week OGTT 0 and 60 minute samples showed that the high
treated animals not only appear to hypersecrete insulin when faced with a glucose
challenge, but that they appear to have higher basal levels of insulin as well (Figure
6.15). The low dose mice did not show the expected increase in insulin levels after a
glucose challenge. Although the reason for this is not clear, it is clear that like the ZDF
rats, Pb exposure did not cause a significant reduction in the capacity of the pancreas to
produce insulin. Although not directly measured, these results are consistent with the
possibility that Pb induces deficiency in peripheral insulin sensitivity.
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Fig. 6.14 – Pb exposure does not affect insulin production in hIAPP mice.
Plasma insulin measured by ELISA showed increasing levels in all groups until week 40. After week
40, both the low and high treated groups’ insulin levels decreased. Data showed no statistical
significance by ANOVA and are means +/- SEM. Week 0 and 14: High control and treated n=16,
Low control and treated n=12. Week 26: High control and treated n=15, Low control n=10 low
treated n=11. Week 40: High control n=13, high treated n=14, low control n=8, low treated n=10.
Week 45: High control n=11, high treated n=13, low control n=7, low treated n=8.

Fig. 6.15 – Pb exposure does not affect insulin production after glucose challenge.
Plasma insulin measured at 40 weeks, before (0 Min) and after (60 Min) glucose bolus showed that
high treated mice began with higher basal levels of insulin than control mice. While both groups’
insulin levels increase proportionally, the high Pb-treated mice appear to hypersecrete insulin. The
low dose mice show no significant difference at 0 and 60 minutes. Data showed no statistical
significance by students T test. Data are means +/- SEM. 40 Weeks: High control n=13 high treated
n=14, low control n=8, low treated n=10.
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A small sample of flash-frozen liver tissue was analyzed for triglyceride content.
These findings revealed that in the high treated animals, Pb exposure induced an
accumulation of triglycerides in the liver (Figure 6.16). Similar findings were observed in
the low dose animals, although the differences were not statistically significant in this
group. Overall however, these data are strongly consistent with the findings from the
ZDF rats; clearly demonstrating that Pb exposure induces hepatic steatosis in rodents.

Fig. 6.16 – Pb exposure causes increased triglyceride accumulation in hIAPP mice.
Liver triglycerides measures showed both high and low dose treated mice had greater accumulations
of triglycerides within the liver tissue. Data analyzed by students T test. Data are means +/- SEM
*p<0.05, **p<0.005. High control n=11, high treated n=13, low control n=7, low treated n=8.
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6.5 – Pb Exposure Effects on Histological Parameters
To determine if Pb exposure affected liver morphology, a portion of the liver from
each animal was subjected to standard histological analyses. Hematoxylin and eosin
(H & E) staining demonstrated that Pb exposure induced the accumulation of lipid
droplets in liver. This occurred at both doses and is consistent with the triglyceride
assay presented above. However, other than the lipid droplets, all of the mice had
normal hepatic lobule structure (Figures 6.17, 6.18, 6.19 and 6.20), showing that Pb
does not have a significant effect on gross liver morphology.
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Fig. 6.17 – High control liver H & E.
Normal hepatic lobular structure is intact. Magnification 10x, bar = 200µm.

Fig. 6.18 – High treated liver H & E.
Lipid droplets are visible within the hepatic tissue of high treated mice.
Magnification 10x, bar = 200µm.
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Fig. 6.19 – Low control liver H & E.
Normal hepatic lobular structure is intact. Magnification 10x, bar = 200µm.

Fig. 6.20 – Low treated liver H & E.
Lipid droplets are visible within the hepatic tissue of low treated mice.
Magnification 10x, bar = 200µm.
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Periodic Acid-Schiff (PAS) stain was used to determine if Pb had any effect on
hepatic glycogen content or distribution. A specimen that is PAS-positive will show
glycogen (carbohydrates) as pink/magenta to purple-violet/red staining. PAS staining
revealed that liver from Pb-exposed animals contained less glycogen than control
animals, as evidenced by the decreased level of PAS-positive staining in both the high
and low Pb-treated mouse liver slides (Figures 6.21, 6.22, 6.23 and 6.24). Glycogen
depletion was further confirmed in the low dose animals by diastase digestion followed
by PAS staining (Figures 6.23 and 6.24). Diastase digestion is often used to confirm
the presence of glycogen in tissue samples, as diastase digestion removes
carbohydrates from tissues, thereby resulting in negative PAS staining in tissues that
had previously been PAS-positive.
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Fig. 6.21 – High control liver PAS.
Numerous PAS-positive glycogen deposits (purple-violet staining) are present
in the control mouse liver. Magnification 20x, bar = 100µm.

Fig. 6.22 – High treated liver PAS. Glycogen depletion after Pb exposure as
evidenced by decreased PAS-positive staining (purple-violet coloration) in the
Pb-treated liver. Magnification 20x, bar = 100µm.
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Fig. 6.23 – Low control liver PAS. Numerous PAS-positive glycogen deposits (purple-violet
staining) are present in the undigested sample (left). But when digested (right), there is a
dramatic loss of PAS-positive staining. Magnification 5x, bar = 1mm.

Fig. 6.24 – Low treated liver PAS. Glycogen depletion after Pb exposure as evidenced by
decreased PAS-positive staining (purple-violet coloration) in the undigested (left) sample.
Digestion (right) does not result in the same dramatic changes as seen in the control mouse
above. Magnification 5x, bar = 1mm.
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To determine if Pb exposure affected pancreatic morphology, a portion of the
pancreas from each animal was subjected to standard histological analyses. H & E
staining demonstrated that Pb exposure does have an effect on islet morphology. Both
high and low control mouse islets appear normal, with a round shape and a well-defined
border (Figures 6.25 and 6.27). However, both high and low Pb-treated mouse islets
are much larger in size than in control animals (Figures 6.26 and 6.28).
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Fig. 6.25 – High control pancreas H & E.
Islets are lighter stained, round areas. Control mice appear to have normal islet
physiology. Magnification 10x, bar = 200µm.

Fig. 6.26 – High treated pancreas H & E.
Islets are lighter stained areas. Pb-treated mice appear to have hypertrophied
islets. Magnification 10x, bar = 200µm.
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Fig. 6.27 – Low control pancreas H & E.
Islets are lighter stained, round areas. Control mice appear to have normal islet
physiology. Magnification 5x, bar = 1mm.

Fig. 6.28 – Low treated pancreas H & E.
Islets are lighter stained areas. Pb-treated mice appear to have hypertrophied
islets. Magnification 5x, bar = 1mm.
.
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Differences in islet sizes were quantified by measuring islet diameter and dividing
them into 3 categories: small (<400µm), medium (>400µm - < 800µm) and large
(>800µm). Figures 6.29 and 6.30 illustrate the distribution of islet sizes in control and
treated groups. While the control groups show a higher proportion of islets in the
smaller size categories, the Pb-treated groups show distributions strongly skewed to the
larger size categories. These findings clearly demonstrate that Pb exposure induces
islet hypertrophy.

In addition, the subjective appearance of the islets from the Pb

exposed mice indicates a general degradation of islet architecture, which is consistent
with the possibility that these islets have at least some degree of compromised
endocrinological function.

Fig. 6.29 – Pb exposure affects islet size
distribution in high dose group. Islets were
counted and divided based on size. High Pb-treated
mice had many larger islets, while the high control
mice had many smaller size islets. Total number of
islets assayed: 254-high treated and 264-high
control.

Fig. 6.30 – Pb exposure affects islet size
distribution in low dose group. Islets were
counted and divided based on size. Low Pbtreated mice had many larger islets, while the
low control mice had many smaller size islets.
Total number of islets assayed: 261-low
treated and 265-low control.
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Noting the Pb-mediated alterations in islet morphology, I wanted to determine if
Pb exposure affected the prevalence of β-cells in pancreatic islets. Aldehyde Fuchsin is
commonly used to detect islets and β-cells in pancreatic tissue samples as blue to violet
or purple punctate in color. Although not easily quantified, the density of dark blue
punctate staining appeared to be increased in the Pb exposed animals.

However,

because the Pb-treated islets are much larger, both groups appear to have the same
proportion of β-cells (Figures 6.31, 6.32, 6.33 and 6.34). These findings, while not
striking, suggest that the increased islet size in Pb-treated mice is related to Pbdependent processes occurring within the islets of these mice.
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Fig. 6.31 – High control pancreas Aldehyde Fuchsin.
Arrows indicate location of islets, and Aldehyde Fuchsin-positive β-cells.
Magnification 20x, bar = 100µm.

Fig. 6.32 – High treated pancreas Aldehyde Fuchsin.
Arrows indicate location of islets, and Aldehyde Fuchsin-positive β-cells.
Magnification 20x, bar = 100µm.
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Fig. 6.33 – Low control pancreas Aldehyde Fuchsin.
Arrows indicate location of islets, and Aldehyde Fuchsin-positive β-cells.
Magnification 20x, bar = 100µm.

Fig. 6.34 – Low treated pancreas Aldehyde Fuchsin.
Arrows denote the edge of the islet (which is too large for the field of view) and
Aldehyde Fuchsin-positive β-cells. Magnification 20x, bar = 100µm.
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6.6 – Pb Exposure Causes Increased Amyloid Plaque Formation
The transgenic mouse model utilized in this study was specifically created to
more closely mimic the human form of diabetes, including amyloid plaque formation. To
determine the extent of amyloidosis within the pancreatic islets of the hIAPP transgenic
mice, a specialized stain for amyloid was utilized. Congo Red is commonly used to
detect amyloid in pancreatic tissue samples, it appears as a bright pink/red stain in a
bright field microscope; while polarized light shows it as an apple-green birefringence.
As is evident from the photos below, both the high and low treated mice had
significantly greater amyloid accumulation within the pancreatic islets (Figures 6.35,
6.36, 6.37 and 6.38).
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Fig. 6.35 – High control pancreas Congo Red, bright field.
Lighter stained areas are islets, pink inside islets is amyloid. Control mice had
very little amyloid. Magnification 5x, bar = 1mm.

Fig. 6.36 – High treated pancreas Congo Red, bright field.
Bright pink and red areas are amyloid positive inside of islets. Treated mice had
significantly more amyloid depositions. Magnification 5x, bar = 1mm.
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Fig. 6.37 – Low control pancreas Congo Red, bright field (left) and polarized (right).
Lighter stained areas are islets; pink inside islets is amyloid (left). Apple-green bi-refringence inside
islets is amyloid deposits. Control mice had very little amyloid. Magnification 5x, bar = 1mm (left),
magnification 10x (right).

Fig. 6.38 – Low treated pancreas Congo Red, bright field (left) and polarized (right).
Lighter stained areas are islets; bright pink-red inside islets is amyloid (left). Apple-green birefringence inside islets is amyloid deposits. Treated mice had significantly more intra-islet amyloid.
Magnification 5x, bar = 1mm (left), magnification 10x (right).
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Quantification of the portion of the islet covered with amyloid was carried out by
dividing islets into 4 categories: no amyloid, low = <1/3 amyloid coverage, medium =
>1/3-<2/3 amyloid coverage and high = >2/3 amyloid coverage (Figures 6.39 and 6.40).
These findings are striking and clearly demonstrate that Pb-exposure exacerbates
amyloid plaque formation in pancreatic islets.

Fig. 6.39 – Pb exposure increases amyloid
plaque formation in high dose group. Islets were
assessed based on surface area filled with amyloid.
High Pb-treated mice had significantly fewer islets
with no amyloid than the high control mice. Total
number of islets assayed: 254-high treated and
264-high control.

Fig. 6.40 – Pb exposure increases amyloid
plaque formation in low dose group. Islets
were assessed based on surface area filled with
amyloid. Low Pb-treated mice had significantly
fewer islets with no amyloid than the low control
mice. Total number of islets assayed: 261-low
treated and 265-low control.
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6.7 – Pb Exposure Affects Liver: Body Weight Ratios
Upon termination and dissection of organs, I noted that livers from control
animals appeared larger than livers from Pb-exposed animals. This observation was
confirmed when the whole excised livers were weighed and liver weights graphed as
percent of body weight (Figure 6.41).

Both the high and low Pb-treated mice had

significantly lower liver-to-body weight ratios than the control mice from both groups.
This was an unexpected finding, especially considering the observed Pb-induced
hepatic steatosis (Figure 6.16), which is usually associated with increased liver weight.
It is well-known that there is a negative correlation between liver size and age
[219-221] and it is possible that Pb exposure accelerated this age-related effect on liver
size, although the mechanism by which this might occur remains obscure.

Fig. 6.41 – Pb exposure affects liver: body weight ratios in hIAPP mice.
Whole liver weights obtained at sacrifice showed that both the high and low Pb-treated
mice had significantly lower liver-to-body weight ratios compared to controls. Data
analyzed by students T test. Data are means +/- SEM *p<0.05, **p<0.005. High control
n=11, high treated n=13, low control n=7, low treated n=8.
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6.8 – Pb Exposure, Whole-Body Insulin Resistance and β-Cell Function
Our lab is not equipped to assess insulin sensitivity by direct measure, so I
utilized an assessment tool that has been widely used in human epidemiological
studies, but is given mixed acceptance when applied to animal studies.

The

homeostatic model assessment (HOMA) is a technique utilized to estimate insulin
resistance and beta-cell function from insulin and fasting blood glucose samples
obtained at the same time. The original HOMA-IR technique, developed in 1985, was
utilized extensively, particularly in clinical and epidemiological studies [222]. However,
the 1985 model did not consider differences in peripheral and hepatic insulin sensitivity,
alterations in insulin secretion or hepatic glucose output when fasting blood glucose
measured above 180 mg/dL, or the presence of circulating pro-insulin. To take into
consideration all of these differences, a modified version of the analysis, termed
HOMA2-IR, was created [223]. The HOMA2-IR model utilizes a computer modeling
program that calculates a corrected nonlinear estimation of insulin resistance (IR) and
percent beta-cell function (% β-cell function).

A number of empirical equations

(nonlinear) are utilized by the HOMA2-IR computer program to predict numerical values
from paired fasting blood glucose and insulin samples. I downloaded the HOMA2-IR
calculator and utilized the fasting blood glucose and insulin measures from weeks 0, 14,
26, 40 and 45 of treatment to view estimated numerical values for the calculations of IR
and % β-cell function between treated and control groups [224].
As demonstrated in Figures 6.42 and 6.43, all groups experienced progressively
increasing insulin resistant and beta-cell function. However, there appears to be a trend
toward greater peripheral insulin resistance in the high treated group.

This is not,
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however a confirmation of insulin resistance and it did not reach statistical significance.
The β-cell graph is consistent with not seeing differences in insulin levels and changes
in β-cell function are directly associated with insulin sensitivity.

Increased beta-cell

function is indicative of decreased peripheral insulin sensitivity and may correlate with βcell hyperplasia.

Fig. 6.42 – Pb exposure affects whole-body insulin resistance in hIAPP mice.
Whole-body insulin resistance as calculated by HOMA2-IR (units are arbitrary) demonstrated that
all groups experienced progressively increasing insulin resistance (IR≤1.0 = non-insulin resistant,
IR>2.7 = insulin resistant). Data are means +/- SEM. Weeks 0 and 14: High control and treated
n=16, Low control and treated n=12. Week 26: High control and treated n=15, Low control n=10 low
treated n=11. Week 40: High control n=13, high treated n=14, low control n=8, low treated n=10.
Week 45: High control n=11, high treated n=13, low control n=7, low treated n=8.
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Fig. 6.43 – Pb exposure affects Beta-cell function in hIAPP mice.
Percent beta-cell function, as calculated by HOMA2-IR (%B=100 = normal beta-cell function,
%B>100 = increased beta-cell function). Data are means +/- SEM. Weeks 0 and 14: High control and
treated n=16, Low control and treated n=12. Week 26: High control and treated n=15, Low control
n=10 low treated n=11. Week 40: High control n=13, high treated n=14, low control n=8, low treated
n=10. Week 45: High control n=11, high treated n=13, low control n=7, low treated n=8.

6.9 – Additional Histological Observations
Liver tissue was examined for fibrosis with Masson’s Trichrome stain, but there
was no discernible difference between the control and Pb-treated in either the high or
low dose groups (data not shown). Pancreatic tissue was also examined for fibrosis
with Masson’s Trichrome Stain, and while there was some fibrosis present, there was
no discernible difference in the degree of fibrosis between the control and Pb-treated in
either the high or low dose groups (data not shown).

6.10 – Discussion of hIAPP Study
The experiments conducted in the hIAPP transgenic mouse model were
designed to determine if Pb-exposure was pro-diabetic in animals with high fat dietinduced obesity, and to specifically determine if Pb-exposure exacerbated the islet
amyloid deposition characteristic of advanced Type 2 diabetes in humans.
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It is clear from the data presented here, that Pb exposure, even at 0.005% w/v, in
combination with the high fat diet, promotes the development of diabetes in hIAPP
transgenic mice, specifically causing the development of fasting hyperglycemia and
glucose intolerance over time.
Even though the hIAPP mice did not experience the same Pb-mediated
elevations in gluconeogenic gene expression as the ZDF rats, this may be accounted
for by differences in termination procedures as well as differences in the physiology of
the two rodents. The ZDF rats were sacrificed under a fasting/re-feeding protocol that
would reveal defects in insulin-mediated suppression of hepatic gluconeogenesis. The
hIAPP mice, on the other hand, were sacrificed after a simple overnight fast (no refeeding period), and liver gene expression levels would be more indicative of the intermeal state, rather than the post-prandial state. In addition, I observed that basal insulin
levels were higher in hIAPP mice (Figures 6.14 and 6.15) than in ZDF rats (Figure 5.9)
which could potentially cause a background suppression of hepatic gene expression
that overpowered any effects of Pb-exposure.

While the dysregulation of the insulin-

mediated suppression of hepatic gluconeogenic gene expression observed in ZDF rats
was not seen in the hIAPP mice; the combination of elevated insulin and blood glucose
levels in the hIAPP mice is suggestive of hepatic insulin resistance.
Consistent with this possibility is the observation of hepatic steatosis in the Pbtreated animals.

Fatty liver is frequently observed in insulin resistant humans and

animal models and is associated specifically with hepatic insulin resistance [201-203].
The hepatic lipid accumulation in both models may be secondary to the hyperglycemia
we observed, which has been shown to be a “trigger” that stimulates de novo synthesis
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of hepatic lipids [204, 205].

Also consistent with Pb-induced metabolic dysfunction

centered on the liver, is the observation that livers from Pb exposed rats were glycogen
depleted (Figures 6.21, 6.22, 6.23 and 6.24). Glycogen depletion has been associated
with elevated fasting blood glucose [200, 206], and may also be consistent with hepatic
insulin resistance. Although not necessarily indicative of hepatic insulin resistance, the
HOMA2-IR assessment (Figures 6.42 and 6.43) demonstrated progressive overall
insulin resistance and increased beta-cell function in the hIAPP mice.
And, while it may seem contradictory, the significant differences in liver-to-body
weight ratios actually accentuate the data showing that Pb exposure affects normal
hepatic function. It is well-known that there is a negative correlation between liver size
and age [219-221]. Decreases in hepatic blood flow are common with age and studies
have shown that decreased ability to clear toxins has caused drug overdoses in the
elderly [219, 220, 225]. It is possible that the age-related effect on hepatic blood flow
decreased clearance of Pb from the liver and exacerbated its effects on hepatic
physiology, including the age-related decrease in liver size.
Examination of gross pancreatic morphology by use of H & E staining revealed
Pb-induced islet hypertrophy in both high and low treatment groups.

This may be

related in part to the strikingly higher level of amyloid deposition in exposed animals.
The data also suggest an increase in beta-cell numbers in the Pb-treated groups, which
may be indicative of classic islet compensation in response to mounting global insulin
resistance, which clearly occurred in the exposed mice (Figures 6.42 and 6.43).
Amyloid accumulations are suggestive of pancreatic dysfunction, which is somewhat
contrary to the observation that insulin levels were not substantially different in Pb-
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exposed vs. control mice. As with the ZDF rats, it appears that while there are striking
Pb-induced islet abnormalities, these alterations are not enough to cause pancreatic
failure, at least within the timeframe of these experiments.
Our results do not rule out the possibility that Pb affects peripheral insulin
resistance in these mice. Unfortunately, a direct measurement of peripheral insulin
sensitivity in intact animals is difficult and was beyond the technical scope of our lab and
my thesis. However, the calculations provided by HOMA2-IR for insulin resistance and
beta-cell function demonstrated a trend in increasing whole-body insulin resistance that
may be accompanied by peripheral insulin resistance.
My findings demonstrate for the first time that Pb promotes the development of
diabetes in a high fat fed transgenic mouse model. I identified Pb-induced defects in
both hepatic glucose output and in postprandial glucose clearance. Both of these are
insulin mediated processes and it seems likely that Pb is interfering with insulin
signaling, at least in liver, and possibly also in muscle. The data also identified key
histological aspects of Pb-exposure, including islet abnormalities and increased β-cell
compensation.

Additionally, the data showed striking Pb-induced exacerbations of

amyloid plaque formations in pancreatic islets. These findings demonstrate that, in
metabolically stressed rodents, Pb exposure increases susceptibility to diabetes and
promotes progressive development of metabolic abnormalities.
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Chapter 7 – Exploring the Molecular Mechanism of Pb Action

The in vivo data presented above demonstrate that Pb exposure causes fasting
hyperglycemia, glucose intolerance and elevated hepatic gluconeogenic gene
expression.

The dysregulation of the insulin-mediated suppression of hepatic

gluconeogenic gene expression and hepatic insulin resistance could be major
contributors to these in vivo observations. To examine the effects of Pb on hepatic
physiology I developed a set of hepatic cell culture systems that reflect the in vivo
consequences of Pb exposure. The overall goal of the in vitro studies using these
systems was to characterize the molecular mechanisms by which Pb alters hepatic
insulin sensitivity and gluconeogenesis. The two aims for this portion of my thesis were
to: 1) determine if Pb exposure alters gluconeogenic gene by interfering with insulin
signaling and 2) determine if Pb exposure alters gluconeogenic gene expression by
interfering with Rev-erb-α activity.

7.1 – Development of the Model Cellular System
The in vivo data described in chapters 5 and 6 suggest that one of the metabolic
effects of Pb exposure in obese rats and mice is to suppress the ability of the liver to
regulate glucose production. Pb concentrations which correlate with blood Pb levels
observed in Pb-exposed individuals were utilized in an effort to make this in vitro system
more clinically relevant [226-229]. In order to decipher the molecular mechanism(s)
responsible for the hepatic effects of Pb, and begin development of the in vitro model
systems, the effect of Pb exposure on hepatic gluconeogenic genes in cultured primary
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rat hepatocytes (PRH) and in two rat hepatoma cell lines were assessed. Extensive
optimization experiments in all three cell systems were carried out to determine
hormonal conditions, treatments times and Pb exposure levels that generated effects on
gluconeogenic gene expression that were most consistent with the in vivo findings (data
not shown).
As will be described in more detail below, the results from these experiments
were consistent with the animal studies in that treatment of liver cells with Pb increased
expression of the two key gluconeogenic genes (PEPCK and G6Pase), as well as the
transcriptional co-activator PGC1-α, which is a strong transcriptional activator of
gluconeogenic gene expression in liver. This effect was seen both on basal gene
expression (Section 7.2) and in the context of insulin mediated suppression of gene
expression (7.3).

7.2 – Pb Stimulates Basal Expression of Key Gluconeogenic Genes
The rat hepatoma cell line FAO was used to examine the effect of Pb on basal
levels of gluconeogenic gene expression. The cells were cultured in serum containing
media in the presence of low levels of insulin. After a 2 hour serum deprivation period
(during which insulin levels were maintained at 1nM) cells were treated with 5µM PbAc
or equimolar NaAc for 8 hours. Cells were washed, lysed by direct application of Tri
reagent and placed on ice.

After mRNA isolation, first-strand cDNA synthesis was

conducted and changes in gluconeogenic gene expression were quantified by qRTPCR with primers for PEPCK, G6Pase, PGC1-α and the housekeeping gene, PPIA. As
shown in Figure 7.1, exposure to Pb induced the expression of genes encoding key
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rate-limiting enzymes involved in glucose biosynthesis (PEPCK and G6Pase) and of the
PGC1-α gene that encodes a transcriptional co-activator that plays a key stimulatory
role in PEPCK gene transcription.

Fig. 7.1 – Pb stimulates the expression of key genes involved in hepatic glucose output in
FAO cells.
Cells were treated with 5µM PbAc or equimolar NaAc in the presence of 1nM insulin. Changes in
expression of key genes (mRNA) were quantified by qRT-PCR with sequence-specific primers.
Data are the mean +/- SEM of three independent experiments. Values are normalized to PPIA;
p*<0.05, p***<0.001.

The data from the FAO cells was supported by collaborative profiling data
generated by Dr. Raymond Novak and Dr. Lowell Overton, Wayne State University
Institute of Environmental Health Sciences (Figure 7.2). The profiling experiments were
conducted in PRH cells treated for 24 hours with 1µM Pb (left panel) and 0.5µM or
5.0µM Pb (right panel) in the presence of the indicated amount of insulin (0, 0.1nM,
1nM, 10nM). These data confirm that Pb exposure stimulates mRNA expression of a
key gluconeogenic co-factor, PGC1-α, as seen in FAO cells. It was noted that PGC1-α
gene expression was stimulated in the presence of Pb, but only when insulin was
present.
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Fig. 7.2 – Pb stimulates the expression of PGC1-α in the presence of insulin.
Primary rat hepatocytes were treated with 1µM (left panel) or with the indicated amount of Pb (right
panel) for 24 hours in the presence of the indicated amount of insulin. In the left panel, note the
suppressive effect of insulin on PGC1-α expression in the absence of Pb. The data in the right panel
(from a separate RNA profiling experiment) are normalized to the vehicle (no Pb) control at each insulin
concentration. Data for left panel are preliminary and were not repeated. Data for right panel are
means +/- SD for two experiments. Data courtesy of Dr. Raymond Novak and Dr. Lowell Overton;
unpublished.

7.3 – Pb Blocks Insulin-Mediated Down-Regulation of PEPCK Gene Expression
Based on data from both FAO cells and preliminary profiling showing that PGC1α gene expression was stimulated by Pb, but only when insulin was present (Figures
7.1 and 7.2), I proposed that the primary effect of Pb on liver glucose metabolism might
be to oppose the well-known insulin-mediated down-regulation of gluconeogenic gene
expression. To examine this, two well-established in vitro cellular models for hepatic
insulin signaling pathways related to glucose production were utilized, primary rat
hepatocytes and H4IIe rat hepatoma cells (the parent cell line of the FAO cells used
above). The pharmacological reagent dexamethasone (Dex) is a glucocorticoid mimic
that is utilized in vitro to stimulate PEPCK gene expression. In this in vitro system, the
effect of insulin on gluconeogenic gene expression is more readily observed in the
presence of dexamethasone. H4IIe cells were serum-starved for 12 hours then treated
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with 500nM dexamethasone (Sigma), 500nM dexamethasone + 10nM Insulin, 10nM
Insulin alone, or vehicle for 4 hours, in the presence of either 50µM PbAc or equimolar
NaAc. Cells were washed with cold PBS after removal of media, lysed with direct
application of Tri reagent and placed on ice. After mRNA isolation, first-strand cDNA
synthesis was conducted and utilized in semi-quantitative PCR with primers specific for
rat PEPCK and housekeeping gene, PPIA.

Final PCR products were analyzed by

agarose gel electrophoresis and quantitative image analysis using a ChemiDoc XRS
imaging system.

Band densities were analyzed using the NIH Image J program

(described in further detail Section 3.10.2).
Figure 7.3 shows the timeline of the experiment, the compiled quantitative data
from three experiments (bar graph) and representative agarose gels of semiquantitative PCR runs.

Figure 7.4 is a subset of the same data from Figure 7.3

assembled for illustrative purposes, to allow an easier comparison between Na-treated
and Pb-treated groups.
The data demonstrate that Pb exposure blocks the suppressive effects of insulin
on PEPCK gene expression. It is also important to note that the ability of Pb to block
insulin’s suppressive effect occurs even in the absence of dexamethasone (last pair of
bars in Fig. 7.4).
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PEPC
K
Fig. 7.3 – Pb blocks insulin-mediated down-regulation of PEPCK gene expression.
H4IIe cells treated withPPIA
500nM Dex, 500nM Dex + 10nM Insulin, 10nM Insulin or Vehicle
(DMSO, PBS & dH2O) for 4 hours plus either 50µM PbAc or 100µM NaAc. Data are means
+/- SEM of three independent experiments.

Fig. 7.4 – Subset of data from Figure 7.3.
Clearly demonstrates the ability of Pb to block insulin-mediated down-regulation of PEPCK
gene expression. H4IIe cells treated with 10nM Insulin or Vehicle (DMSO, PBS & dH 2O) for 4
hours plus either 50µM PbAc or 100µM NaAc. Data are means +/- SEM of three independent
experiments. P values relative to PPIA control, ** p< 0.001
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Similar experiments in primary hepatocytes showed analogous results.

PRH

cells were plated on collagen-coated plates in insulin-containing media and allowed to
recover overnight. Cells were subjected to a 2 hour incubation in insulin-free media and
then treated with 50μM PbAc or equimolar NaAc and either PBS (Veh) or 10nM insulin
for 24 hr. Semi-quantitative PCR carried out as described above generated the results
shown in Figure 7.5. Pb blunted the insulin-mediated suppression of PEPCK gene
transcription in PRH cells in a manner similar to that seen in H4IIe cells in Figure 7.3
and in the right hand panel of Figure 7.5.
These gene expression results are consistent with the observation made by our
colleagues Ray Novak and Lowell Overton (WSU IEHS) who kindly provided data from
an experiment in primary hepatocytes showing the insulin mediated Akt phosphorylation
was suppressed by Pb (Figure 7.6). As Akt mediates the insulin signal leading to
suppression of FoxO1, which is required for PEPCK, G6Pase and PGC1-α expression

Fig. 7.5 – Pb blunts the ability of insulin to suppress PEPCK gene expression.
Primary rat hepatocytes (left) were treated with 50μM PbAc or equimolar NaAc and either PBS
(Veh) or 10nM insulin for 24 hr. PEPCK mRNA levels were measured by qRT-PCR with
sequence-specific primers. Data for PRH cells are preliminary and were not repeated. The
same experiment was conducted in H4IIe rat hepatoma cells (right) except that treatment time
was for 4 hours. In both cell systems, Pb strongly blunted the suppressive effects of insulin.
Data for H4IIe cells are the mean +/- SEM of three independent experiments.
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(see Figure 2.1). These findings suggest a possible mechanism by which Pb exposure
alters insulin-mediated changes in gene expression.

Fig. 7.6 – Pb inhibits Akt phosphorylation in presence of insulin.
Primary rat hepatocytes were treated with increasing concentrations of insulin for 24 hours, which
resulted in a dose-responsive increase in Akt phosphorylation (left part of figure). This insulinmediated phosphorylation of Akt was strongly suppressed by the inclusion of 0.5µM Pb in the media
and completely blocked by 5µM Pb. Data were preliminary, not repeated, and are courtesy of Dr.
Raymond Novak and Dr. Lowell Overton; unpublished.

7.4 – Pb, Rev-erb-α and Effects on Basal PEPCK Gene Expression
To examine the effects of Pb exposure on basal PEPCK gene expression in
relation to the orphan nuclear receptor Rev-erb-α, H4IIe rat hepatoma cells were
utilized. Emerging evidence indicates that components of the circadian clock machinery
can regulate expression of metabolic genes, including PEPCK, G6Pase and PGC1-α
[155]. This evidence was further supported by data gathered from mice with mutated
Clock genes showing abnormal gluconeogenic gene expression [156-158]. However,
the mechanism that links metabolic gene expression to circadian clock rhythms remains
poorly understood.
Recently, studies have shown that heme functions as an endogenous ligand for
the orphan nuclear receptor Rev-erb-α, a known component of the circadian clock
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machinery [159]. Rev-erb-α is highly expressed in multiple tissues including liver, and
functions as a transcriptional repressor [160, 163]. When heme is bound, it facilitates
the interaction of Rev-erb-α with the nuclear receptor corepressor-histone deacetylase 3
(NCoR-HDAC3) complex [160-162].

When heme binds to Rev-erb-α it initiates

recruitment of the NCoR-HDAC3 complex and suppresses the transcription of Rev-erbα target genes including PEPCK, G6Pase and PGC1-α [161]. It is well established that
Pb interferes with heme biosynthesis by direct inhibition of δ-aminolevulinic acid
synthetase (δ-ALAS), δ-aminolevulinic acid dehydratase (δ-ALAD) and causing an
accumulation of the known pro-oxidant, δ-ALA [164-167].

Taken together, these

observations suggest the following model (Figure 7.7).

Pb exposure leads to

suppression of heme biosynthesis and a reduction in intracellular heme levels. The
reduction in intracellular heme leads to reduced ability of Rev-erb-α to suppress gene
transcription and thereby an increase in the expression of PEPCK, G6Pase and PGC1α.

The resulting increase in gluconeogenic gene expression will lead to elevated

hepatic glucose production, contributing to the pathogenesis of diabetes.
The overall experimental strategy to test this model is divided into three stages.
First, establish a system in hepatoma cell lines and primary hepatocytes in which we
can confirm the previously reported effects of heme on PEPCK and G6Pase
transcriptional activity. Commercially available well-characterized reagents to artificially
alter intracellular heme levels were used to establish the experimental parameters.
Succinyl acetone (Sigma D1415) to suppress heme biosynthesis and hemin, (Sigma
H9030) to increase intracellular heme levels were used as previously described [159,
161]. Once this system was established it was to be used to examine the specific role
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of Rev-erbα in regulation of PEPCK and G6Pase gene transcription. This was to be
accomplished using a combination of luciferase reporter constructs containing highly
specific Rev-erb-α DNA binding sites (ROREs) upstream of a minimal promoter, as well
as PEPCK and G6Pase promoter/reporter constructs that we already have available in
the lab. The ability of Pb to reduce the suppressive activity of Rev-erb-α on PEPCK and
G6Pase gene transcription would constitute evidence in support of the model described
above.
Extensive optimization experiments in multiple cell lines (H4IIe hepatoma, CHO,
NIH 3T3 and HepG2 cells) were conducted to elicit an effect of Pb on Rev-erb-α. While
I was able to observe an effect from exogenous heme on luciferase reporter gene
activity, the results were inconsistent; and, to date, I have been unable to see a clear
effect of Pb on Rev-erb-α activity (data not shown).

Fig. 7.7 – Rev-erb-α model for how Pb stimulates PEPCK gene expression.
Based on recently published data demonstrating the link between Rev-erb-α and
its ligand, heme; along with the ability of Pb to suppress heme biosynthesis.

122
7.5 – Discussion of In Vitro Studies
PEPCK gene expression is controlled by multiple transcription factors and cofactors. Some of the transcription factors that play key roles in PEPCK gene expression
are FoxO1, Rev-erb-α and the co-activator, PGC1-α [141, 230-233]. Hepatic insulin
signals involving Akt-mediated phosphorylation and subsequent translocation of FoxO1
outside of the nucleus plays a central role in regulation of PEPCK gene transcription
[234-236]. The transcriptional rate of PEPCK gene plays a major role in regulating
hepatic glucose production and output, and its suppression by insulin plays a key role in
the maintenance of normal plasma glucose levels.

Therefore, in an effort to

characterize the molecular mechanism of Pb in the liver, the in vitro system was
optimized to observe maximal effects of Pb on PEPCK.
Although I was able to show clearly that Pb exposure in vitro caused an elevation
in PEPCK gene expression and a reduction in the ability of insulin to suppress PEPCK
expression, I was not successful in identifying the exact molecular mechanism by which
this occurred. The two proposed mechanisms; blocking insulin signaling upstream of
Akt, and reducing the suppressive effects of Rev-erb-α by blocking production of its
ligand heme, are still both viable possibilities.
The combination of data presented here related to alterations in gluconeogenic
gene expression and insulin signaling in PRH and rat hepatoma cells after Pb exposure
suggests that a major consequence of Pb in the liver is hepatic insulin resistance.
Figure 7.8 is proposed as a model for the role of Pb involvement in insulin signaling.
As described above, the results from these experiments are consistent with the
animal studies; in vitro treatment of liver cells with Pb either induced the expression of
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genes that are required for hepatic glucose production (PEPCK, G6Pase, and PGC1-α),
or blocked the ability of insulin to down-regulate these genes. The dysregulation of the
insulin-mediated suppression of hepatic gluconeogenic gene expression could be a
major contributor to the hyperglycemia observed in the animal studies and further
supports the supposition that Pb exposure causes hepatic insulin resistance. Together,
these observations suggest that Pb exposure interferes with insulin signaling, inducing a
hepatic insulin resistance that compromises the ability of the liver to control glucose
production and promotes the development of hyperglycemia, consistent with in vivo
observations.
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Fig. 7.8 – Hypothetical model of how
Pb may inhibit insulin signaling.
This model is based on preliminary data
of how Pb functions to alter insulin
signaling and hepatic gluconeogenesis
in the liver.
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ABSTRACT
LINKING ENVIRONMENTAL TOXICANT
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An important and unresolved question in the environmental health field is
whether exposure to common environmental toxicants, such as dioxin and heavy metals
like Pb, increase the risk of developing diabetes, especially in combination with other
common metabolic stressors such as obesity.
Previous studies suggested that dioxin exposure increased peripheral insulin
resistance but did not appear to cause fasting hyperglycemia or elevated hepatic
glucose output. In concordance with those findings we observed that dioxin treatment
caused a strong suppression of the expression of the key hepatic gluconeogenic genes
PEPCK and G6Pase. However, this suppression was not solely mediated by the dioxin
(AhR) receptor as we observed that dioxin treatment stimulated the AMPK signaling
pathway, which is known to have a suppressive effect on PEPCK gene expression.
Although Pb exposure and blood Pb levels have declined over the past decade,
the interaction between obesity and Pb exposure is a relevant issue in large sections of
the US population where environmental and lifestyle factors co-exist with exposure to
persistent environmental toxicants, such as Pb.

We characterized the effect of Pb
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exposure on diabetes risk in metabolically stressed rodents and attempted to identify
the in vitro mechanisms by which Pb affects metabolic balance.
These findings demonstrate for the first time that, in metabolically stressed
rodents, Pb exposure promotes the development of Type 2 diabetes. In ZDF rats we
identified Pb-induced defects in hepatic glucose output and postprandial glucose
clearance as well as key histological aspects of Pb-exposure, including islet
abnormalities and increased β-cell compensation. And in hIAPP transgenic mice we
demonstrated that Pb exposure, in combination with a high fat diet, caused the
development of fasting hyperglycemia and glucose intolerance as well as Pb-induced
islet hyperplasia and striking pancreatic amyloid plaque formation. In vitro data from
cultured hepatocytes clearly showed that Pb exposure either induced the expression of
genes that are required for hepatic glucose production (PEPCK, G6Pase, and PGC1-α),
or blocked the ability of insulin to down-regulate those genes, which would contribute to
the development of hyperglycemia in vivo. Together, these observations suggest that
Pb exposure interferes with insulin signaling, inducing a hepatic insulin resistance that
compromises the ability of the liver to control glucose production.
Understanding the cooperative interaction between toxicant exposure and
additional physical and social stressors that may promote metabolic instability and
disease will be of enormous significance in delineating disease/toxicant etiology as well
as establishing earlier interventions for those populations most at risk.
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